[go: up one dir, main page]

US20190010538A1 - Saliva collection, processing, stabilization, and storage method - Google Patents

Saliva collection, processing, stabilization, and storage method Download PDF

Info

Publication number
US20190010538A1
US20190010538A1 US16/015,407 US201816015407A US2019010538A1 US 20190010538 A1 US20190010538 A1 US 20190010538A1 US 201816015407 A US201816015407 A US 201816015407A US 2019010538 A1 US2019010538 A1 US 2019010538A1
Authority
US
United States
Prior art keywords
sample
saliva
protein
nucleic acid
filtered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US16/015,407
Inventor
David T. Wong
Wei Liao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Priority to US16/015,407 priority Critical patent/US20190010538A1/en
Assigned to THE REGENTS OF THE UNIVERSITY OF CALIFORNIA reassignment THE REGENTS OF THE UNIVERSITY OF CALIFORNIA ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: LIAO, WEI, WONG, DAVID T.
Publication of US20190010538A1 publication Critical patent/US20190010538A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B10/00—Instruments for taking body samples for diagnostic purposes; Other methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determination; Throat striking implements
    • A61B10/0045—Devices for taking samples of body liquids
    • A61B10/0051—Devices for taking samples of body liquids for taking saliva or sputum samples
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/40—Concentrating samples
    • G01N1/4005—Concentrating samples by transferring a selected component through a membrane
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
    • Y10T436/2525—Stabilizing or preserving

Definitions

  • the present disclosure relates to an apparatus and methods for the analysis of protein and nucleic acids present in cell-free samples of saliva.
  • Saliva has been used to detect, for example, caries risk, peridontitis, oral cancer, breast cancer, lung cancer, Sjögren's syndrome, salivary gland disease and infectious diseases such as hepatitis, HIV, and HCV. Saliva is therefore an attractive diagnostic sample alternative for blood, serum, or plasma.
  • Saliva is ideal for nucleic acid analysis.
  • the human salivary transcriptome in cell-free saliva was first discovered in 2004 by use of microarray technology (Li et al, J. Dent. Res. 83:199-203 (2004)). Investigations into the characteristics of salivary RNA followed, which led to the development of salivary transcriptomics as a research focus. (Park et al., Clin. Chem 52:988-94 (2006); Park et al. Arch. Oral. Biol., 52:30-5 (2007)).
  • Saliva is additionally ideal for proteomic analysis.
  • Profiling proteins in saliva over the course of disease progression can reveal biomarkers indicative of different stages of diseases, which can be useful in early detection and/or medical diagnosis (Hu et al., Proteomics 6:6326 (2006)).
  • Proteomics is widely envisioned as a unique and powerful approach to biomarker development. As proteomic technologies continue to mature, proteomics has the great potential for salivary proteomic biomarker development and further clinical applications (Xiao and Wong, Bioinformation 5:294 (2011); Zhang et al, Mol. Diagn. Ther. 13:245 (2009)).
  • Saliva is an ideal translational research tool and diagnostic medium and is being used in unique ways to provide molecular biomarkers for a variety of oral and systemic diseases and conditions.
  • the ability to analyze saliva to monitor health and disease is highly desirable for oral health promotion and research.
  • Saliva has been used to detect caries risk, periodontitis, oral cancer, breast cancer, salivary gland disease, and infectious diseases such as hepatitis, HIV, and HCV. Measurement of salivary analytes requires optimal collection, processing and storage procedures and conditions.
  • a method for stabilizing RNA and protein samples isolated from a saliva sample includes a) collecting a saliva sample from a subject; b) filtering the saliva sample to produce a filtered sample that is free of cells; c) collecting the filtered sample in at least a first and a second receiving device; d) adding an alcohol solution to the first receiving device to produce an alcohol-containing filtered sample comprising a protein sample, with the proviso that alcohol is not added to the second receiving device to produce an alcohol-free filtered sample comprising a nucleic acid sample; wherein the protein sample and the nucleic acid sample are stabilized for at least 3 days when stored at 25 degrees Celsius; and e) performing an analysis on the filtered sample collected in the first and second receiving devices comprising one or more of: a protein analysis on the alcohol-containing filtered sample or a nucleic acid analysis on the alcohol-free filtered sample.
  • the nucleic acid is DNA.
  • the nucleic acid analysis is polymerase chain reaction (PCR).
  • PCR polymerase chain reaction
  • the nucleic acid is RNA.
  • the nucleic acid analysis is RT-PCR.
  • the RT-PCR is reverse transcription quantitative real-time PCR (RT-qPCR).
  • the ethanol solution comprises 20% ethanol.
  • the ethanol solution comprises 15-25% ethanol.
  • the ethanol solution comprises 5-35% ethanol.
  • the protein analysis comprises western blot, mass spectrometry protein identification, or ELISA.
  • the filtered sample is stored at ambient temperature. In a further embodiment, in accordance with any of the above embodiments or in combination with any of the above embodiments, the filtered sample is stored at ambient temperature for at least two weeks without more than 50% degradation of proteins or nucleic acids present in the filtered sample.
  • the filtered sample is stored at ambient temperature for at least two weeks without more than 25% degradation of proteins or nucleic acids present in the filtered sample. In a further embodiment, in accordance with any of the above embodiments or in combination with any of the above embodiments, the filtered sample is stored at ambient temperature for at least ten weeks without more than 50% degradation of proteins or nucleic acids present in the filtered sample. In a further embodiment, in accordance with any of the above embodiments or in combination with any of the above embodiments, the filtered sample is stored at ambient temperature for at least ten weeks without more than 25% degradation of proteins or nucleic acids present in the filtered sample.
  • the filter is selected from the group consisting of a 0.22 ⁇ m, 0.45 ⁇ m and 5.0 ⁇ m hydrophilic membrane. In a further embodiment, in accordance with any of the above embodiments or in combination with any of the above embodiments, the filter is a 0.22 ⁇ m hydrophilic membrane.
  • an apparatus for the collection of saliva samples for biomarker detection comprises a sample collection pad, a filter, two or more receiving devices, wherein the receiving devices are selected from an mRNA collection tube, a polypeptide collection tube, and a DNA collection tube, wherein the polypeptide collection tube comprises an ethanol solution, and the DNA collection tube comprises a DNA stabilizer, wherein the filter is operably connected to the receiving devices.
  • the filter is selected from the group consisting of a 0.22 ⁇ m, 0.45 ⁇ m or 5.0 ⁇ m hydrophilic membrane. In a further embodiment, in accordance with any of the above embodiments or in combination with any of the above embodiments, the filter is a 0.22 ⁇ m hydrophilic membrane. In a further embodiment, in accordance with any of the above embodiments or in combination with any of the above embodiments, a method of using the apparatus is provided.
  • the method includes inserting the sample collection pad into the oral cavity for sufficient time to moisten the sample collection pad, inserting the collection pad into the receiving tube, applying sufficient force to cause the materials collected in the collection pad to pass through the filter thereby forming a filtered sample, and collecting the filtered sample into one or more receiving devices.
  • a method for stabilizing RNA and protein samples isolated from a saliva sample includes a) collecting a saliva sample from a human subject; b) filtering the saliva sample using a 0.22 ⁇ m to 5.0 ⁇ m hydrophilic membrane to produce a filtered sample that is free of cells; c) collecting the filtered sample in at first and a second receiving device; d) adding an ethanol solution to the first receiving device to produce a 20% ethanol-containing filtered sample comprising a protein sample, with the proviso that alcohol is not added to the second receiving device to produce an alcohol-free filtered sample comprising a nucleic acid sample; wherein the protein sample and the nucleic acid sample are stabilized for at least 3 days when stored at 25 degrees Celsius.
  • the method further comprises the step of (e) performing an analysis on the filtered samples collected in the first and second receiving devices comprising one or more of: a protein analysis on the ethanol-containing filtered sample or a nucleic acid analysis on the alcohol-free filtered sample.
  • the protein sample is stabilized for at least 2 weeks when stored at 25 degrees Celsius.
  • the nucleic acid sample is stabilized for at least 10 weeks when stored at 25 degrees Celsius.
  • the ethanol solution comprises 15-25% ethanol. In a further embodiment, in accordance with any of the above embodiments or in combination with any of the above embodiments, the ethanol solution comprises 5-35% ethanol. In a further embodiment, in accordance with any of the above embodiments or in combination with any of the above embodiments, the hydrophilic membrane in 0.22 ⁇ m.
  • FIG. 1 illustrates a schematic diagram of the experimental design of Example 1.
  • FIG. 2 illustrates the effect of DNA removal by the described DNase treatment procedures as demonstrated using human cell genomic DNA (300 ⁇ g/ml) as template. Solid bars represent GAPDH, white bars represent ACTB, and striped bars represent RPS9.
  • FIG. 3 illustrates expression levels of 3 SIRG mRNAs analyzed by standard procedures and the DSTA method at day 0.
  • FIG. 4 illustrates expression levels of 3 SIRG mRNAs measure during 10 weeks of storage at ambient temperature without stabilizing reagent.
  • FIG. 5 illustrates box-and-whisker plots showing the Cq value distributions of 90 clinical samples used in the validation study of OSCC salivary transcripts.
  • the results of each transcript were displayed individually in (A) H3F3A; (B) IL1B; (C) IL8; (D) OAZi; (E) SAT1; (F) DUSP1, and (G) S100P.
  • Each transcript was detected in 27 OSCC and 63 normal subjects by standard and streamlined procedures at Day 0 and Week 10 (DSTA method only), which were represented by 1-6 on X axis: 1: Normal subjects assayed by standard procedures; 2: OSCC subjects assayed by standard procedures; 3: Normal subjects assayed by the SDTA method of Day 0; 4: OSCC subjects assayed by the DSTA method at Day 0; 5: Normal subjects assayed by the DSTA method at Week 10; and 6: OSCC subjects assayed by the DSTA method at Week 10.
  • Y axis is represented by raw Cq value in each plot.
  • FIG. 6 illustrates (A) ROC curves for 7 OSCC salivary transcripts that was each detected by standard procedures, (B) ROC curves for 7 OSCC salivary transcripts that each was detected by the DSTA at day 0, and (C) ROC curves for 7 OSCC salivary transcripts that each was detected by the DSTA at week 10.
  • FIG. 7 illustrates a schematic diagram of the saliva sample collection and experimental design of Example 2.
  • RT w/E room temperature with adding 20% ethanol (a) without amylase depletion; (b) with amylase depletion.
  • FIG. 10 illustrates Protein stabilization by denaturing.
  • A Western blot of ⁇ -actin, RT w/B: RT with boiling, RT w/e: RT with 20-time volumes ethanol added
  • FIG. 11 illustrates western blot of ⁇ -actin (A) with and without adding ethanol at day 3, day 7 and day 14.
  • RT w/E room temperature with 20% ethanol added.
  • A Stored for 7 days
  • B Stored for 14 days
  • C Stored for 30 days.
  • RT w/E room temperature with 20% ethanol added.
  • FIG. 13 illustrates depicts a scheme of saliva collection, processing, stabilization and storage (SCPSS) as described in Example 3.
  • SPSS saliva collection, processing, stabilization and storage
  • Human saliva contains an array of analytes (proteins, mRNA, and DNA) that can be used as biomarkers for translational and clinical applications.
  • saliva can be used to detect, caries risk, peridontitis, oral cancer, breast cancer, lung cancer, Sjögren's syndrome, salivary gland disease and infectious diseases such as hepatitis, HIV, and HCV.
  • a value of using saliva as a source of biomarkers is the ease of sampling and high subject compliance for sample collection. Presence of RNAs and protein in the cell-free fluid phase portion of saliva was confirmed by the procedures described extensively in the Examples. However, current methods for the extraction of nucleic acids and protein from saliva require the saliva sample to be processed immediately after collection using special instrumentation and trained personnel, the addition of nucleic acid and protein stabilizers, and storage at ⁇ 80° C.
  • the ability to provide a user friendly and easy to use collector apparatus for major salivary diagnostic analytes is of interest.
  • the present invention provides methods and an apparatus for the collection of saliva and saliva biomarkers. The methods can be carried out by non-professionals in a user friendly integrated point-of-care collection system that allows storage and shipment at room temperature without the addition of commonly used nucleic acid and protein stabilizers.
  • a “saliva sample” refers to samples derived from saliva from an animal that produces saliva. Saliva is a component of oral fluid produced in most animals.
  • a “filtered sample” refers to a saliva sample that has been processed to remove cells by separating the cell-phase and the fluid phase of saliva.
  • a filtered sample can have more than 50%, more than 75%, more than 95%, or a 100% removal of cells.
  • a sample is filtered to avoid mechanical rupture of cellular elements that could contribute to the detection of unwanted analytes in the cell-free phase.
  • a filtered sample can further exclude extraneous substances, including but not limited to, food debris.
  • alcohol solution refers to any solution containing an alcohol such as methanol, isopropyl alcohol, and ethanol.
  • An alcohol solution can contain, for example, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, or 100% alcohol, e.g., ethanol.
  • alcohol-containing filtered sample refers to a cell free saliva sample comprising an alcohol, e.g., an ethanol solution, as described herein.
  • alcohol-free filtered sample refers to a cell free saliva sample that is at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% free of alcohol, including but not limited to, isopropyl alcohol, methanol, or ethanol.
  • analysis refers to any quantitative or qualitative examination or measurement of saliva components.
  • analyses that determine the presence or absence of nucleic acids or proteins; over or under expression of nucleic acids or proteins; or a genomic, transcriptomic, or proteomic examination of a saliva sample.
  • a collection apparatus refers to any apparatus that can be used to collect saliva.
  • a collection apparatus includes a sample collection pad as described herein, a filter that is capable of separating cells from a sample as described herein, and a receiving device that is capable of receiving the filtered sample as described herein.
  • collection pad refers to any material that is suitable for collection of saliva. Examples can include, but are not limited to, nitrocellulose, cellulose acetate, polyethersulfur fabric, cellulose fiber such as paper strips or cotton, nylon, gel foam, fiber glass, polycarbonate, polyproplene, acetate, rayon, polyester absorbent pad, or other synthetic materials capable of collecting saliva.
  • filter refers to any filter capable of separating cells from a saliva sample.
  • filters can include, but are not limited to, cellulose fiber matrix, hydrophilic filters, such as those based on polyvinylidene fluoride membrane, or filters based on polypropylene membrane. Filters can have micropores that are a wide variety of sizes, including, but not limited to, 0.22 ⁇ m, 0.45 ⁇ m and 5.0 ⁇ m.
  • filtering refers to the application of a liquid sample containing cells, e.g. a saliva sample, to a membrane filter. Filtering is the process of removing cells and/or parts of cells from excess fluid in a liquid sample by passing the sample through a microporous membrane filter.
  • free of cells refers to a sample solution that has been filtered in accordance with the methods of the present invention such that the sample solution is completely or substantially cell-free.
  • degradation refers to, for example, the proteolytic cleavage of proteins into smaller peptides and amino acids; or the catalysis of nucleic acids into smaller components. Degradation as used herein results in proteins and nucleic acids having compromised gene expression and clinical utilities.
  • receiving device refers to any device capable of collecting a filtered sample.
  • Receiving devices can include, but are not limited to, devices formed wholly or partially from plastic, such as polypropylene, polystyrene, polycarbonate, polyurethane, or polyethylene, polycarbonate, polytetrafluoroethylene, enamel, nylon, ceramic or any combination thereof, or from glass and/or metallic materials.
  • Receiving devices can be, for example, snap cap, screw cap, and loop-cap microcentrifuge tubes.
  • ambient temperature is the temperature of the surrounding environment, which generally refers to room temperature in a clinical setting. Ambient temperature is generally between 20 and 25 degrees Celsius.
  • extracellular refers to fluidic space outside the plasma membranes of cells.
  • the composition of the extracellular space can include proteins, nucleic acids, lipids, hormones, microbial product, etc.
  • stabilizing refers to any effect of the methods according to the present invention resulting in the stabilization of the structure and/or activity of a biomolecule, the elongation of the shelf-life of a biomolecule and/or the protection of a biomolecule against stress. This results in a biological activity of the biomolecule which is retained to a significant degree.
  • exemplary stabilizations can be nucleic acids or proteins that are stabilized for 2 to 10 weeks or more at room temperature.
  • nucleic acid refers to deoxyribonucleotides or ribonucleotides and polymers thereof in either single- or double-stranded form, and complements thereof.
  • the term refers to all forms of nucleic acids (e.g., gene, pre-mRNA, mRNA) and their polymorphic variants, alleles, mutants, and interspecies homologs.
  • nucleic acid is used interchangeably with gene, cDNA, mRNA, oligonucleotide, and polynucleotide.
  • the term encompasses nucleic acids that are naturally occurring or recombinant.
  • Nucleic acids can (1) code for an amino acid sequence that has greater than about 60% amino acid sequence identity, 65%, 70%, 75%, 80%, 85%, 90%, preferably 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% or greater amino acid sequence identity, preferably over a region of at least about 25, 50, 100, 200, 500, 1000, or more amino acids, to a polypeptide encoded by a referenced nucleic acid or an amino acid sequence described herein; (2) specifically bind to antibodies, e.g., polyclonal antibodies, raised against an immunogen comprising a referenced amino acid sequence, immunogenic fragments thereof, and conservatively modified variants thereof; (3) specifically hybridize under stringent hybridization conditions to a nucleic acid encoding a referenced amino acid sequence, and conservatively modified variants thereof, (4) have a nucleic acid sequence that has greater than about 95%, preferably greater than about 96%, 97%, 98%, 99%, or higher nucleotide sequence identity
  • polypeptide “peptide” and “protein” are used interchangeably herein to refer to a polymer of amino acid residues.
  • the terms apply to amino acid polymers in which one or more amino acid residue is an artificial chemical mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers and non-naturally occurring amino acid polymer.
  • amino acid refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function in a manner similar to the naturally occurring amino acids.
  • Naturally occurring amino acids are those encoded by the genetic code, as well as those amino acids that are later modified, e.g., hydroxyproline, ⁇ -carboxyglutamate, and O-phosphoserine.
  • Amino acid analogs refers to compounds that have the same basic chemical structure as a naturally occurring amino acid, e.g., an a carbon that is bound to a hydrogen, a carboxyl group, an amino group, and an R group, e.g., homoserine, norleucine, methionine sulfoxide, methionine methyl sulfonium. Such analogs have modified R groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as a naturally occurring amino acid.
  • Amino acid mimetics refers to chemical compounds that have a structure that is different from the general chemical structure of an amino acid, but that functions in a manner similar to a naturally occurring amino acid.
  • Amino acids may be referred to herein by either their commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Nucleotides, likewise, may be referred to by their commonly accepted single-letter codes.
  • a protein, nucleic acid, antibody, or small molecule compound refers to a binding reaction that is determinative of the presence of the protein or nucleic acid, such as the differentially expressed genes of the present invention, often in a heterogeneous population of proteins or nucleic acids and other biologics.
  • a specified antibody may bind to a particular protein at least two times the background and more typically more than 10 to 100 times background. Specific binding to an antibody under such conditions requires an antibody that is selected for its specificity for a particular protein.
  • polyclonal antibodies can be selected to obtain only those polyclonal antibodies that are specifically immunoreactive with the selected antigen and not with other proteins. This selection may be achieved by subtracting out antibodies that cross-react with other molecules.
  • a variety of immunoassay formats may be used to select antibodies specifically immunoreactive with a particular protein.
  • solid-phase ELISA immunoassays are routinely used to select antibodies specifically immunoreactive with a protein (see, e.g., Harlow & Lane, Antibodies, A Laboratory Manual (1988) for a description of immunoassay formats and conditions that can be used to determine specific immunoreactivity).
  • Embodiments described herein include a streamlined, ambient-temperature processing, stabilization, and storage of nucleic acids derived from saliva.
  • Direct saliva transcriptome and genome analyses using cell-free saliva supernatant instead of isolated nucleic acids, which include the processing, stabilization, and storage of saliva samples, as described herein, can be performed at ambient temperature without stabilization agents.
  • stabilization agents can be included.
  • alcohol can be included.
  • nucleic acid stabilization requiring extremely low temperatures or nucleic acid stabilization chemicals can be impractical for field applications or daily clinical operations.
  • nucleic acid stabilizers can affect downstream analyses. Described herein is the extraction of extracellular nucleic acids that can be stored at ambient temperatures until needed for downstream applications, such as PCR, without the need for additional stabilization chemicals.
  • the nucleic acids of the present invention can be stored at room temperature for longer than 1 week, 2 weeks, 5 weeks, 10 weeks, or 25 weeks or more.
  • nucleic acids in a form that is suitable for detection following collection of the cell-free salivary sample is well known in the art.
  • Such methods can include, but are not limited to, PCR, reverse transcriptase-PCR (RT-PCR), real-time PCR, reverse transcription quantitative real-time PCR (RT-qPCR), ligase chain reaction, strand displacement amplification (SDA), self-sustained sequence replication (3SR), or in situ PCR.
  • RT-PCR reverse transcriptase-PCR
  • RT-qPCR reverse transcription quantitative real-time PCR
  • SDA strand displacement amplification
  • 3SR self-sustained sequence replication
  • Any suitable qualitative or quantitative methods known in the art for detecting specific nucleic acid e.g., RNA or DNA
  • Nucleic acid can be detected by, for example, by reverse transcriptase-PCR, or in Northern blots containing poly A mRNA, and other methods well known in the art.
  • PCR amplification techniques are described in, e.g., Ausubel et al. and Innis et al., supra. General nucleic acid hybridization methods are described in Anderson, “Nucleic Acid Hybridization,” BIOS Scientific Publishers, 1999.
  • a temperature of about 36° C. is typical for low stringency amplification, although annealing temperatures may vary between about 32° C. and 48° C. depending on primer length.
  • a temperature of about 62° C. is typical, although high stringency annealing temperatures can range from about 50° C. to about 65° C., depending on the primer length and specificity.
  • Typical cycle conditions for both high and low stringency amplifications include a denaturation phase of 90° C.-95° C. for 30 sec-2 min., an annealing phase lasting 30 sec.-2 min., and an extension phase of about 72° C. for 1-2 min. Protocols and guidelines for low and high stringency amplification reactions are provided, e.g., in Innis et al., PCR Protocols, A Guide to Methods and Applications, Academic Press, Inc. N.Y. (1990).
  • RNA extraction can be performed by any method know to those of skill in the art, e.g., methods involving proteinase K tissue digestion and alcohol-based nucleic acid precipitation, treatment with DNase to digest contaminating DNA, RNA purification using silica-gel-membrane technology, methods utilizing commercially available kits such as Trizol and RNeasy, or any combination thereof.
  • Real time RT-PCR can be performed by any method known to those of skill in the art, e.g., Taqman real time PCR using Applied Biosystem assays.
  • Nucleic acid primers, or probes can be generated using the polynucleotide sequences disclosed herein.
  • the probes are preferably at least about 12, 15, 16, 18, 20, 22, 24, or 25 nt fragments of a contiguous sequence of nucleic acid or polypeptide.
  • the probes can be produced by, for example, chemical synthesis, PCR amplification, generation from longer polynucleotides using restriction enzymes, or other methods well known in the art.
  • Nucleic acid probes can be used as diagnostics wherein a biological sample to be analyzed, such as saliva, can be treated, if desired, to extract the nucleic acids contained therein.
  • the resulting nucleic acid from the sample can be subjected to gel electrophoresis or other size separation techniques; alternatively, the nucleic acid sample can be dot blotted without size separation.
  • the nucleic acids extracted from the sample are then treated with the labeled probe under hybridization conditions of suitable stringencies.
  • the probes can be made completely complementary to the target nucleic acid or portion thereof (e.g., to all or a portion of a sequence encoding a target). Therefore, usually high stringency conditions are desirable in order to prevent or at least minimize false positives.
  • conditions of high stringency should only be used if the probes are complementary to regions of the target which lack heterogeneity.
  • the stringency of hybridization is determined by a number of factors during hybridization and during the washing procedure, including temperature, ionic strength, length of time, and concentration of formamide (Sambrook et al. (1989), “Molecular Cloning; A Laboratory Manual,” Second Edition (Cold Spring Harbor Press, Cold Spring Harbor, N.Y.)).
  • Nucleic acid probes can be provided in solution for such assays, or can be affixed to a support (e.g., solid or semi-solid support).
  • a support e.g., solid or semi-solid support.
  • supports that can be used are nitrocellulose (e.g., in membrane or microtiter well form), polyvinyl chloride (e.g., in sheets or microtiter wells), polystyrene latex (e.g., in beads or microtiter plates, polyvinylidine fluoride, diazotized paper, nylon membranes, activated beads, and Protein A beads.
  • Non-PCR-based, sequence specific DNA amplification techniques can also be used with the invention to detect nucleic acids.
  • An example of such techniques include, but is not necessarily limited to, the Invader assay (see, e.g., Kwiatkowski et al. Mol Diagn. 1999, 4:353-64. See also U.S. Pat. No. 5,846,717).
  • Nucleic acids can be detectably labeled.
  • detectable labels include, but are not limited to, radiolabels, fluorochromes, (e.g. fluorescein isothiocyanate (FITC), rhodamine, Texas Red, phycoerythrin, allophycocyanin, 6-carboxyfluorescein (6-FAM), 2′,7′-dimethoxy-4′,5′-dichloro-6-carboxyfluorescein, 6-carboxy-X-rhodamine (ROX), 6-carboxy-2′,4′,T,4,7-hexachlorofluorescein (HEX), 5-carboxyfluorescein (5-FAM) or N,N,N′,N′-tetramethyl-6-carboxyrho-damine (TAMRA)), radioactive labels, (e.g.
  • fluorochromes e.g. fluorescein isothiocyanate (FITC), rhodamine,
  • the detectable label can involve two stage systems (e.g., biotin-avidin, hapten-anti-hapten antibody, and the like).
  • Analysis of nucleic acid mutations derived from saliva samples can be performed using techniques known in the art including, without limitation, electrophoretic analysis or sequence analysis.
  • electrophoretic analysis include slab gel electrophoresis such as agarose or polyacrylamide gel electrophoresis, capillary electrophoresis, and denaturing gradient gel electrophoresis (DGGE).
  • slab gel electrophoresis such as agarose or polyacrylamide gel electrophoresis
  • capillary electrophoresis capillary electrophoresis
  • denaturing gradient gel electrophoresis DGGE
  • nucleic acid analysis includes, but is limited to, restriction analyses such as restriction-fragment-length-polymorphism detection based on allele-specific restriction-endonuclease cleavage (Kan and Dozy, Lancet ii:910-12 (1978)), hybridization with allele-specific oligonucleotide probes (Wallace et al., Nucl. Acids Res. 6:3543-3557 (1978)), including immobilized oligonucleotides (Saiki et al., PNAS 86:6230-6234 (1989)), oligonucleotide arrays (Maskos and Southern, Nucl. Acids Res.
  • restriction analyses such as restriction-fragment-length-polymorphism detection based on allele-specific restriction-endonuclease cleavage (Kan and Dozy, Lancet ii:910-12 (1978)), hybridization with allele-specific oligonucleotide probes (
  • Non-limiting examples of sequence analysis include Maxam-Gilbert sequencing, Sanger sequencing, capillary array DNA sequencing, thermal cycle sequencing (Sears et al., Biotechniques, 13:626-633 (1992)), solid-phase sequencing (Zimmerman et al., Methods Mol. Cell Biol., 3:39-42 (1992)), sequencing with mass spectrometry such as matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF/MS; Fu et al., Nat.
  • MALDI-TOF/MS matrix-assisted laser desorption/ionization time-of-flight mass spectrometry
  • Probes can be provided on an array for detection following saliva extraction.
  • Arrays can be created by, for example, spotting polynucleotide probes onto a substrate (e.g., glass, nitrocellulose, and the like) in a two-dimensional matrix or array.
  • the probes can be bound to the substrate by either covalent bonds or by non-specific interactions, such as hydrophobic interactions.
  • Samples of polynucleotides can be detectably labeled (e.g., using radioactive or fluorescent labels) and then hybridized to the probes.
  • Double stranded polynucleotides comprising the labeled sample polynucleotides bound to probe polynucleotides, can be detected once the unbound portion of the sample is washed away.
  • Techniques for constructing arrays and methods of using these arrays are described in EP 799 897; WO 97/29212; WO 97/27317; EP 785 280; WO 97/02357; U.S. Pat. No. 5,593,839; U.S. Pat. No. 5,578,832; EP 728 520; U.S. Pat. No. 5,599,695; EP 721 016; U.S. Pat. No. 5,556,752; WO 95/22058; and U.S. Pat.
  • Arrays are particularly useful where, for example a single sample is to be analyzed for the presence of two or more nucleic acid target regions, as the probes for each of the target regions, as well as controls (both positive and negative) can be provided on a single array. Arrays thus facilitate rapid and convenience analysis.
  • Embodiments described herein include a streamlined, ambient-temperature processing, stabilization, and storage of proteins derived from saliva.
  • Direct saliva proteomic analyses using cell-free saliva supernatant instead of isolated proteins, which include the processing, stabilization, and storage of saliva samples, as described herein, can be performed at ambient temperature.
  • Protein stabilization requiring extremely low temperatures or protein stabilization chemicals can be impractical for field applications or daily clinical operations.
  • protein stabilizers can affect downstream analyses. In some embodiments, protein stabilizers can be used. In other embodiments, protein stabilizers are not used. In other embodiments, ethanol can be used to stabilize the salivary proteins of the present invention.
  • Alcohol can include, but it not limited to, ethanol. Alcohol can be added, for example, at concentrations of 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95% alcohol. Alcohol can be added, for example, at concentrations of 25-35%, 20-40%, 15-45%, 10-50%, 5-50%.
  • the nucleic acids of the present invention can be stored at room temperature for longer than 1 week, 2 weeks, 5 weeks, 10 weeks, or 25 weeks or more.
  • Extracellular protein can be purified to substantial purity by standard techniques, including selective precipitation with such substances as ammonium sulfate; column chromatography, immunopurification methods, and others (see, e.g., Scopes, Protein Purification: Principles and Practice (1982); U.S. Pat. No. 4,673,641; Ausubel et al, supra; and Sambrook et al., supra).
  • the molecular weight of the protein can be used to isolate it from proteins of greater and lesser size using ultrafiltration through membranes of different pore size (for example, Amicon or Millipore membranes).
  • membranes of different pore size for example, Amicon or Millipore membranes.
  • the protein mixture is ultrafiltered through a membrane with a pore size that has a lower molecular weight cut-off than the molecular weight of the protein of interest.
  • the retentate of the ultrafiltration is then ultrafiltered against a membrane with a molecular cut off greater than the molecular weight of the protein of interest.
  • the recombinant protein will pass through the membrane into the filtrate.
  • the filtrate can then be chromatographed.
  • the protein can also be separated from other proteins on the basis of its size, net surface charge, hydrophobicity, and affinity for ligands or substrates using column chromatography.
  • antibodies raised against proteins can be conjugated to column matrices and the proteins immunopurified. All of these methods are well known in the art. It will be apparent to one of skill that chromatographic techniques can be performed at any scale and using equipment from many different manufacturers (e.g., Pharmacia Biotech).
  • Antibody reagents can be used in assays to detect proteins in saliva samples using any of a number of immunoassays known to those skilled in the art. Immunoassay techniques and protocols are generally described in Price and Newman, “Principles and Practice of Immunoassay,” 2nd Edition, Grove's Dictionaries, 1997; and Gosling, “Immunoassays: A Practical Approach,” Oxford University Press, 2000. A variety of immunoassay techniques, including competitive and non-competitive immunoassays, can be used. (See, e.g., Self et al., Curr. Opin. Biotechnol 7:60-65 (1996)).
  • immunoassay encompasses techniques including, without limitation, enzyme immunoassays (EIA) such as enzyme multiplied immunoassay technique (EMIT), enzyme-linked immunosorbent assay (ELISA), IgM antibody capture ELISA (MAC ELISA), and microparticle enzyme immunoassay (META); immunohistochemical assay, capillary electrophoresis immunoassays (CEIA); radioimmunoassays (RIA); immunoradiometric assays (IRMA); fluorescence polarization immunoassays (FPIA); and chemiluminescence assays (CL). If desired, such immunoassays can be automated. Immunoassays can also be used in conjunction with laser induced fluorescence.
  • EIA enzyme multiplied immunoassay technique
  • ELISA enzyme-linked immunosorbent assay
  • MAC ELISA IgM antibody capture ELISA
  • MEA microparticle enzyme immunoassay
  • immunohistochemical assay capillary electro
  • Liposome immunoassays such as flow-injection liposome immunoassays and liposome immunosensors, are also suitable for use in the present invention. (See, e.g., Rongen et al., J. Immunol. Methods, 204:105-133 (1997)).
  • nephelometry assays in which the formation of protein/antibody complexes results in increased light scatter that is converted to a peak rate signal as a function of the marker concentration, are suitable for use in the methods of the present invention.
  • Nephelometry assays are commercially available from Beckman Coulter (Brea, Calif.; Kit #449430) and can be performed using a Behring Nephelometer Analyzer (Fink et al., J Clin. Chem. Clin. Biochem., 27:261-276 (1989)).
  • detectable moiety can be used (direct or indirect detection).
  • detectable moieties are well known to those skilled in the art, and can be any material detectable by spectroscopic, photochemical, biochemical, immunochemical, electrical, optical or chemical means. Detectable moieties can be used, with the choice of label depending on the sensitivity required, ease of conjugation with the antibody, stability requirements, and available instrumentation and disposal provisions.
  • Suitable detectable moieties include, but are not limited to, radionuclides, fluorescent dyes (e.g., fluorescein, fluorescein isothiocyanate (FITC), Oregon GreenTM, rhodamine, Texas red, tetrarhodimine isothiocynate (TRITC), Cy3, Cy5, etc.), fluorescent markers (e.g., green fluorescent protein (GFP), phycoerythrin, etc.), autoquenched fluorescent compounds that are activated by tumor-associated proteases, enzymes (e.g., luciferase, horseradish peroxidase, alkaline phosphatase, etc.), nanoparticles, biotin, digoxigenin, metals, and the like.
  • fluorescent dyes e.g., fluorescein, fluorescein isothiocyanate (FITC), Oregon GreenTM, rhodamine, Texas red, tetrarhodimine isothiocyn
  • Direct labels include fluorescent or luminescent tags, metals, dyes, radionucleodies, and the like, attached to the antibody.
  • An antibody labeled with iodine-125 (1251) can be used.
  • a chemiluminescence assay using a chemiluminescent antibody specific for nucleic acids or proteins is suitable for sensitive, non-radioactive detection of nucleic acids or protein levels.
  • An antibody labeled with fluorochrome is also suitable. Examples of fluorochromes include, without limitation, DAPI, fluorescein, Hoechst 33258, R-phycocyanin, B-phycoerythrin, R-phycoerythrin, rhodamine, Texas red, and lissamine.
  • Indirect labels include various enzymes well known in the art, such as horseradish peroxidase (HRP), alkaline phosphatase (AP), ⁇ -galactosidase, urease, and the like.
  • HRP horseradish peroxidase
  • AP alkaline phosphatase
  • ⁇ -galactosidase urease, and the like.
  • a horseradish-peroxidase detection system can be used, for example, with the chromogenic substrate tetramethylbenzidine (TMB), which yields a soluble product in the presence of hydrogen peroxide that is detectable at 450 nm.
  • TMB tetramethylbenzidine
  • An alkaline phosphatase detection system can be used with the chromogenic substrate p-nitrophenyl phosphate, for example, which yields a soluble product readily detectable at 405 nm.
  • a ⁇ -galactosidase detection system can be used with the chromogenic substrate o-nitrophenyl- ⁇ -D-galactopyranoside (ONPG), which yields a soluble product detectable at 410 nm.
  • An urease detection system can be used with a substrate such as urebromocresol purple (Sigma Immunochemicals; St. Louis, Mo.).
  • Other proteins capable of specifically binding immunoglobulin constant regions, such as protein A or protein G can also be used as a label agent. These proteins exhibit a strong non-immunogenic reactivity with immunoglobulin constant regions from a variety of species (see, e.g., Kronval et al., J. Immunol. 111:1401-1406 (1973); Akerstrom et al., J. Immunol. 135:2589-2542 (1985).
  • Western blot (immunoblot) analysis can be used to detect and quantify the presence of an antigen in the sample.
  • the technique generally comprises separating sample proteins by gel electrophoresis on the basis of molecular weight, transferring the separated proteins to a suitable solid support, (such as a nitrocellulose filter, a nylon filter, or derivatized nylon filter), and incubating the sample with the antibodies that specifically bind the antigen.
  • the anti-antigen antibodies specifically bind to the antigen on the solid support.
  • These antibodies can be directly labeled or alternatively can be subsequently detected using labeled antibodies (e.g., labeled sheep anti-mouse antibodies) that specifically bind to the anti-antigen antibodies.
  • An ELISA method can be used as follows: (1) bind an antibody or antigen to a substrate; (2) contact the bound receptor with a fluid or tissue sample containing the virus, a viral antigen, or antibodies to the virus; (3) contact the above with an antibody bound to a detectable moiety (e.g., horseradish peroxidase enzyme or alkaline phosphatase enzyme); (4) contact the above with the substrate for the enzyme; (5) contact the above with a color reagent; (6) observe color change.
  • a detectable moiety e.g., horseradish peroxidase enzyme or alkaline phosphatase enzyme
  • the above method can be readily modified to detect presence of an antibody in the sample or a specific protein as well as a virus.
  • An antigen and/or a subject's antibodies to the virus can be detected utilizing a capture assay.
  • antibodies to an immunoglobulin e.g., anti-IgG (or IgM) are bound to a solid phase substrate and used to capture the patient's immunoglobulin from serum.
  • the antigen, or reactive fragments of the antigen are then contacted with the solid phase followed by addition of a labeled antibody.
  • the amount of specific antibody can then be quantitated by the amount of labeled antibody binding.
  • a micro-agglutination test can also be used to detect the presence of an antigen in test samples.
  • latex beads are coated with an antibody and mixed with a test sample, such that the antigen in the tissue or body fluids that is specifically reactive with the antibody crosslink with the receptor, causing agglutination.
  • the agglutinated antibody-virus complexes within a precipitate visible with the naked eye or by spectrophotometer.
  • Competitive assays can also be adapted to provide for an indirect measurement of the amount of an antigen present in the sample. Briefly, serum or other body fluids from the subject is reacted with an antibody bound to a substrate (e.g. an ELISA 96-well plate). Excess serum is thoroughly washed away. A labeled (enzyme-linked, fluorescent, radioactive, etc.) monoclonal antibody is then reacted with the previously reacted antibody complex. The amount of inhibition of monoclonal antibody binding is measured relative to a control. Monoclonal antibodies (MABs) can also be used for detection directly in samples by IFA for MABs specifically reactive for the antibody-antigen complex.
  • a substrate e.g. an ELISA 96-well plate
  • a labeled (enzyme-linked, fluorescent, radioactive, etc.) monoclonal antibody is then reacted with the previously reacted antibody complex. The amount of inhibition of monoclonal antibody binding is measured relative to a control.
  • a hapten inhibition assay is another competitive assay.
  • the known antigen can be immobilized on a solid substrate.
  • a known amount of anti-antigen antibody is added to the sample, and the sample is then contacted with the immobilized antigen.
  • the amount of antibody bound to the known immobilized antigen is inversely proportional to the amount of antigen present in the sample.
  • the amount of immobilized antibody can be detected by detecting either the immobilized fraction of antibody or the fraction of the antibody that remains in solution. Detection can be direct where the antibody is labeled or indirect by the subsequent addition of a labeled moiety that specifically binds to the antibody as described above.
  • Immunoassays in the competitive binding format can also be used for crossreactivity determinations.
  • an antigen can be immobilized to a solid support. Proteins can be added to the assay that competes for binding of the antisera to the immobilized antigen. The ability of the added proteins to compete for binding of the antisera to the immobilized protein is compared to the ability of the antigen to compete with itself. The percent crossreactivity for the above proteins is calculated, using standard calculations. Those antisera with less than 10% crossreactivity with each of the added proteins listed above are selected and pooled. The cross-reacting antibodies are optionally removed from the pooled antisera by immunoabsorption with the added considered proteins, e.g., distantly related homologs.
  • the immunoabsorbed and pooled antisera can then be used in a competitive binding immunoassay as described above to compare a second protein, thought to be perhaps an allele or polymorphic variant of an antigen, to the immunogen protein.
  • the two proteins are each assayed at a wide range of concentrations and the amount of each protein required to inhibit 50% of the binding of the antisera to the immobilized protein is determined. If the amount of the second protein required to inhibit 50% of binding is less than 10 times the amount of the antigen that is required to inhibit 50% of binding, then the second protein is said to specifically bind to the polyclonal antibodies generated to antigen.
  • a signal from a direct or indirect label can be analyzed, for example, using a spectrophotometer to detect color from a chromogenic substrate; a radiation counter to detect radiation such as a gamma counter for detection of 1251; or a fluorometer to detect fluorescence in the presence of light of a certain wavelength.
  • a radioactive label means for detection include a scintillation counter or photographic film as in autoradiography.
  • the label is a fluorescent label, it can be detected by exciting the fluorochrome with the appropriate wavelength of light and detecting the resulting fluorescence. The fluorescence can be detected visually, by the use of electronic detectors such as charge coupled devices (CCDs) or photomultipliers and the like.
  • enzymatic labels can be detected by providing the appropriate substrates for the enzyme and detecting the resulting reaction product. Colorimetric or chemilluminescent labels can be detected simply by observing the color associated with the label. Thus, in various dipstick assays, conjugated gold often appears pink, while various conjugated beads appear the color of the bead.
  • a quantitative analysis can be made using a spectrophotometer such as an EMAX Microplate Reader (Molecular Devices; Menlo Park, Calif.) in accordance with the manufacturer's instructions. If desired, the assays of the present invention can be automated or performed robotically, and the signal from multiple samples can be detected simultaneously.
  • the antibodies can be immobilized onto a variety of solid supports, such as magnetic or chromatographic matrix particles, the surface of an assay plate (e.g., microtiter wells), pieces of a solid substrate material or membrane (e.g., plastic, nylon, paper), and the like.
  • An assay strip can be prepared by coating the antibody or a plurality of antibodies in an array on a solid support. This strip can then be dipped into the test sample and processed quickly through washes and detection steps to generate a measureable signal, such as a colored spot.
  • Embodiments of the invention described herein relate to the analysis of extracellular nucleic acids and proteins derived from a cell-free fluid phase portion of saliva.
  • Saliva Collection, Processing, Stabilization, and Storage (SCPSS) is designed as an all-in-one kit to collect, process, stabilize, and store saliva samples for research and clinical applications such as molecular diagnostics based on protein, RNA, and DNA.
  • nucleic acids and proteins were confirmed by the procedures described in the Examples.
  • the quality of the detected nucleic acids and proteins meet the demand for techniques such as PCR, qPCR, microarray assays, ELISA, Western blot, etc.
  • Suitable absorbent materials can include, but are not limited to, nitrocellulose, cellulose acetate, polyethersulfur fabric, cellulose fiber such as paper strips or cotton, nylon, gel foam, fiber glass, polycarbonate, polyproplene, acetate, rayon, polyester absorbent pad, or other synthetic materials capable of collecting saliva. Any other method known in the art can be used to collect saliva. For example, the spitting method can also be used as a means of collecting a sample of saliva.
  • An alternative method of obtaining saliva samples is a method whereby saliva is sucked out of the oral cavity by means of an aspirator. Saliva that has collected in the oral cavity can also be simply dripped out into a sample vessel.
  • the absorbent pad can be individually placed into a syringe having a filter attached to the end of the syringe.
  • the filter can be any type of filter described herein capable of separating saliva into a cell-free and fluid phase, for example, a 5.0 ⁇ m hydrophilic PVDF filter (Millex-SV, Millipore).
  • the syringe plunger can then be used to push the saliva out of the pad and through the filter into a collection tube ( FIG. 7 ).
  • the tubes can be pre-loaded with specific stabilizer for protein, RNA, and DNA.
  • the tubes can also be pre-loaded with an alcohol solution.
  • the collection apparatus can be any type of commercial collection pad.
  • the SUPER ⁇ SAL or VERSI ⁇ SAL collection devices can be used to collect saliva samples and further configured to be used with a sample filtration apparatus.
  • the saliva collection device can separate samples into two or more aliquots following filtration.
  • An exemplary device for dual separation is the ULTRA ⁇ SAL-2 saliva collection device (Oasis Diagnostics, Vancouver, Wash.) ( FIG. 13 ).
  • An embodiment describes the apparatus described herein in a method of for collecting saliva.
  • the method can include inserting the sample collection pad into the oral cavity for sufficient time to moisten the sample collection pad, inserting the collection pad into the receiving tube, applying sufficient force to cause the materials collected in the collection pad to pass through the filter thereby forming a filtered sample, and collecting the filtered sample into one or more receiving devices.
  • nucleic acid and protein can be analyzed, e.g., virus, prions, bacteria (e.g., Mycobacterium tuberculosis ), carbohydrates such as sugars, lipids, fatty acids, hormones, cholesterol, metabolites, and small molecule drug compounds.
  • the apparatus can be used to diagnose a disease in a subject.
  • the disease can include, but is not limited to, lung cancer, breast cancer stomach cancer, liver cirrhosis, a failing kidney, ulcer cancer, ovarian cancer, uterus cancer, cervical cancer, oral cancer, esophageal cancer, thyroid cancer, larynx cancer, leukemia, colon cancer, bladder cancer, prostate cancer, bronchus cancer, pancreas cancer, caries risk, periodontitis, salivary gland disease, head cancer, neck cancer, skin cancer, diabetes, smoking status, and infectious diseases such as hepatitis, HIV, and HCV.
  • the apparatus can be used to monitor pH levels in a subject.
  • the apparatus can be used to test for use of a drug including, but not limited to, prescription and controlled drugs, alcohol, methamphetamine, cocaine, caffeine, morphine, codeine, amphetamine, ephedrine, narcotine, DMT, and MDMA.
  • a drug including, but not limited to, prescription and controlled drugs, alcohol, methamphetamine, cocaine, caffeine, morphine, codeine, amphetamine, ephedrine, narcotine, DMT, and MDMA.
  • Standard operating procedures for salivary transcriptomic analysis require low temperatures and lengthy mRNA isolation processes.
  • This example describes a streamlined, ambient-temperature processing, stabilization, and storage protocol for clinical analysis of salivary RNA.
  • DSTA Direct Saliva transcriptome analysis
  • SS saliva supernatant
  • RT-qPCR reverse transcription quantitative real-time PCR
  • Saliva samples were collected, according to protocols approved by an institutional review board, from 5 healthy individuals (mean age 34 years) who gave informed consent. None of the individuals had a history of malignancy, immunodeficiency, autoimmune disorder, hepatitis, or HIV infection (Table 1).
  • the DNase-treated SS (product from aliquot #2) was employed as a contrast group to reflect DNA interference in the raw SS (product from aliquot #1).
  • Isolated mRNA (product from aliquot #3) was applied to standard procedures of saliva RNA detection, and was employed as a positive control to evaluate the DSTA method performance. All the SS samples (products from aliquots #1 and #2) were stored at room temperature (25° C.) without stabilizing reagent, and the isolated mRNAs were frozen at ⁇ 80° C. until use.
  • the RT-qPCR assay was used in all samples to detect mRNA expression levels of 3 saliva internal reference genes (SIRGs): glyceraldehyde-3-phosphate dehydrogenase (GAPDH), 9 actin, beta (ACTB), and ribosomal protein S9 (RPS9).
  • SIRGs saliva internal reference genes
  • GPDH glyceraldehyde-3-phosphate dehydrogenase
  • ACTB 9 actin, beta
  • RPS9 ribosomal protein S9
  • a case-control salivary biomarker study was further conducted to examine the feasibility of clinical applications of the DSTA method associated with long-term ambient temperature storage.
  • Ninety samples were collected from 3 institutions, including 27 samples from patients with oral squamous cell carcinoma (OSCC) and 63 samples from healthy controls (see Table 2).
  • OSCC oral squamous cell carcinoma
  • mRNAs from 7 OSCC salivary biomarker genes human H3 histone family 3A (H3F3A), interleukin1-beta (IL1B), interleukin 8 (IL8), ornithine decarboxylase antizyme 1 (OAZ1), spermidine/spermine N1-acetyltransferase 1 (SAT1), dual specificity phosphatase1 (DUSP1), and S100 calcium binding protein P (S100P) (Li et al. Clin. Cancer Res. 10:8442-50 (2004)).
  • H3F3A human H3 histone family 3A
  • IL1B interleukin1-beta
  • IL8 interleukin 8
  • OFAZ1 ornithine decarboxylase antizyme 1
  • SAT1 spermidine/spermine N1-acetyltransferase 1
  • DUSP1 dual specificity phosphatase1
  • S100P S100 calcium binding protein P
  • biomarker genes were used as the proof-of-concept markers and tested in all study participants. Quantification of the 7 transcripts in 90 samples was performed concurrently by standard and DSTA methods at day 0 and after 10 weeks of ambient temperature storage without a stabilizing reagent. The feasibility of the DSTA method for the clinical applications was evaluated by the numbers of markers that could be discriminated, and their diagnostic performances were compared to the results obtained by standard procedures.
  • Salivary mRNA was isolated from 300 ⁇ L SS ( FIG. 1 , aliquot #3 of each study participant) using a King-Fisher® instrument (Thermo Electron Corporation) with a MagMAX Viral RNA Isolation Kit® (Applied Biosystems). The isolated mRNA was then treated with a TURBO DNA-free kit, followed by DNase inactivation to remove DNA contamination. The purity of the isolated mRNA was assessed by use of the A260/A280 ratio (accepted range: 1.8-2.0) with an ND-1000 spectrophotometer (Thermo Scientific). The complete removal of DNA in the isolated mRNA was demonstrated by qPCR without reverse transcription (see FIG. 2 ).
  • RT-qPCR reverse transcription-PCR
  • qPCR reverse transcription-PCR
  • Table 4 Multiplex RT-PCR preamplification of 3 SIRG mRNAs was performed by using a SuperScript III platinum qRT-PCR System (Invitrogen) with a pool of outer primer sets (200 nmol/L for each; see Table 4), and conducted by a GeneAmp PCR-System 9700 (Applied Biosystems) with a fixed thermal cycling program (see Table 5).
  • Each study participant provided 6 L raw SS, 7.08 ⁇ L DNase-treated SS, and 2 ⁇ L isolated mRNA as 3 different templates for RT-PCR, in which the samples were equalized by the mRNA volume.
  • RT-PCR samples In addition to the 15 experimental RT-PCR samples (5 study participants 3 templates per study participant), a negative control with nuclease-free water as the reactive template (i.e., a blank group) was prepared. The total volume of each reaction was 30 ⁇ L adjusted by nuclease free water.
  • the RT-PCR products were purified by ExoSAP-IT (USB) and immediately applied to qPCR or stored at ⁇ 20° C. until use.
  • SYBR Green qPCR was performed to quantitatively detect the expression levels of salivary transcripts.
  • the qPCR sample was prepared by combining 2 ⁇ qPCR Mastermix (Applied Biological Materials), inner primers (900 nmol/L; see Table 4), and 2 ⁇ L cDNA template. The total volume of each reaction was 10 ⁇ L adjusted by nuclease-free water.
  • the qPCR associated with melting-curve analysis was conducted by use of an AB-7500HT System (Applied Biosystems) with a fixed thermal-cycling program (Table 6). Each gene was tested in triplicate for all samples, including the negative control in which the cDNA template was the product of negative control in RT-PCR preamplification. All primers used in RT-qPCR were designed with intron spanning by use of PRIMER3 software and produced by Sigma after a BLAST search.
  • cell-free SS was used as a template to detect mRNA expression levels for 3 SIRGs and compared the results to results obtained with standard procedures.
  • the results shown in FIG. 3 are for detection performed immediately after saliva samples were collected (day 0).
  • the Cq value in the water group is the mean of triplicate qPCR experiments, and showed 33 for all 3 genes.
  • the water group did not show any peak in the melting-curve analysis (data not shown), no matter which SIRG primers were used, indicating there was no reagent contamination during the RT-qPCR procedures.
  • the Cq value of each gene in the experimental setups was the mean of results for samples from 5 healthy study participants, each of which was assayed in triplicate (total 15 data points).
  • the Cq values obtained from the raw SS (DSTA) were 22.84 (2.36), 21.57 (1.63), and 20.35 (1.39), whereas the Cq acquired from isolated mRNAs were 25.28 (1.44), 23.16 (2.2), and 21.42 (1.33) for GAPDH, ACTB, and RPS9, respectively.
  • the P values obtained by comparing the Cq values from SS (DSTA) and isolated mRNA for each SIRG were 0.092, 0.233, and 0.247 for GAPDH, ACTB, and RPS9, respectively.
  • melting-curve analyses were conducted along with each qPCR run. A single peak with similar melting temperature was observed for the same gene in all samples (data not shown).
  • the P values were 0.645, 0.13, and 0.58 for GAPDH, ACTB, and RPS9, respectively ( FIG.
  • saliva samples were stored at 25° C. (laboratory ambient temperature), and the 3 SIRG mRNA expression levels were assayed by using RT-qPCR at day 0 and after 1, 2, and 10 weeks of storage.
  • the mean Cq values detected by SS increased slightly after 10 weeks of preservation and showed no significant difference throughout the time course (P>0.05; FIG. 4 ; P values: SS(DSTA)-Week X vs SS (DSTA)-Day 0 at X10).
  • the Cq values obtained by using SS were all similar to those detected by isolated mRNA(P>0.05) at each time point ( FIG. 4 ; P value: SS(DSTA) vs isolated mRNA at day 0 and weeks 1, 2, and 10).
  • DNase-treated SS samples were used to assess DNA contamination for the duration of ambient temperature storage.
  • the mean Cq values were all similar to the results detected by raw SS(P>0.05) at each time point, indicating no DNA interference was present in the DSTA procedure ( FIG. 4 ; P values: SS (DSTA) vs SS+DNase at day 0 and weeks 1, 2, and 10).
  • H3F3A, IL1B, IL8, OAZ1, and SAT1 and 4 (H3F3A, IL1B, IL8, and DUSP1) of the salivary oral cancer markers were validated by both standard procedures and the DSTA method at day 0 and week 10, respectively.
  • 4 markers (H3F3A, IL1B, IL8, and SAT1) at day 0 and 3 markers (H3F3A, IL1B, and IL8) at week 10 exhibited higher ROC-plot AUC values when assayed by use of the DSTA protocol (see Table 7 FIG. 6 ).
  • Saliva RNA detection is an emerging field in molecular diagnostics (Martin et al. Cancer Res. 70:5203-6 (2010)). This study aimed to develop a robust, easy-to-use, ambient-temperature compatible, and cost-effective protocol to further advance the use of saliva transcriptomes for translational and clinical applications.
  • RNA profiles in exosomes showed that ribosomal RNA was absent and most of the RNA molecules were ⁇ 200 nucleotides in length (Skog et al, Nat. Cell Biol. 10:1470 (2008)), which is in alignment with the mean size of salivary mRNA.
  • Saliva samples were collected from 10 healthy subjects. None of the subjects had any history of malignancy, immunodeficiencies, autoimmune disorders, hepatitis, and/or HIV infection, and had a mean age of 35 years. Subjects were asked to refrain from eating, drinking or using oral hygiene products for at least 1 h prior to collection. After rinsing their mouths with water, 5 mL saliva was collected from each subject into a 50 mL Falcon tube.
  • FIG. 7 is the schematic diagram for the sample preparation.
  • Saliva amylase depletion was conducted according to a previous report (Deutsch et al. Electrophoresis 29:4150 (2008)). Briefly, saliva samples were eluted from starch column to deplete amylase specifically.
  • saliva samples were either boiled at 95° C. for 10 min or by adding 20-time volumes absolute ethanol (Fisher Scientific, NJ, USA). Denatured samples were kept at RT for two weeks. The saliva proteins were then precipitated by centrifugation at 20,000 g for 20 min.
  • IV For the non-denaturing method, every 20 ⁇ L absolute ethanol was added to 100 ⁇ L saliva. All the samples were made up to equal volume with distilled water. At different time points, 1 aliquot of saliva sample that has been kept at RT or 4° C. was moved into a ⁇ 80° C. freezer and stored until further analysis.
  • the protein concentration of each saliva sample was measured by using the BCA Protein Assay Kit (Thermo Scientific Pierce, Ill., USA). Equal volume of each sample was loaded into a 96 well plate in duplicates. The experiment was performed according to the manufacturer's instruction and the plate was read at 562 nm.
  • Equal volume of each saliva sample was used for SDS-PAGE and western blot.
  • SDS-PAGE the 10% Bis-Tris gel was run at 150V in MES SDS Running Buffer for 1 h. Pre-stained protein standard (Invitrogen, CA, USA) was used to track protein migration. The gel was then stained with simple blue (Invitrogen, CA, USA).
  • saliva proteins were run and transferred to a PVDF membrane using the iBlot (Invitrogen, CA, USA). The membrane was incubated with the primary antibody (mouse monoclonal antibody to actin, Sigma-Aldrich, St.
  • Tandem (version 2010.04.21).
  • the parameters for searching were enzyme trypsin, 1 missed cleavage, fixed modifications of carbamidomethyl (C), variable modifications of oxidation (M), parent ion tolerance 4 Da and fragment mass tolerance: ⁇ 0.4 Da.
  • the criteria of two peptides and log (E-value) ⁇ 10 were used for protein identification.
  • ⁇ -actin Total ⁇ -actin Sandwich ELISA Kit, Cell Signaling Technology, Inc., MA, USA
  • MP Thermo Scientific Pierce, Ill., USA
  • the Graphpad Prism (Version 5.01) was used for all data analysis. P value was calculated based on T test and p ⁇ 0.05 was used as cutoff for significance. One-way ANOVA was run to determine whether the groups are actually different in the measured characteristic. The signal intensity of the western blot bands was quantified by using the Image J software (NIH, Bethesda, Md., USA).
  • protease inhibitors are usually added during sample collection to prevent proteolysis. This investigation also assessed protease cocktail and different temperature conditions on proteome stabilization, because they are known to greatly affect the rate proteolysis (Chevalier et al, Clin. Proteomics 3:13 (2007)). Amylase removal may increase the stability of other salivary proteins and eases the characterization of low abundant proteins (Hu et al, Proteomics 6:6326 (2006). Ethanol has been fully evaluated for the stabilization of protein (Gekko and Timasheff, Biochemistry 20:4677 (1981). All these methods were tested and evaluated for their efficiency in proteome stabilization.
  • the protein concentrations of saliva samples stored at RT and ⁇ 80° C. were measured.
  • the average total protein concentration the positive control was 1.19 ⁇ 0.15 ⁇ g ⁇ L ⁇ 1 after stored at ⁇ 80 for 30 days.
  • ⁇ -actin in human saliva was degraded when the samples when stored at RT.
  • the stability of ⁇ -actin was systematically compared among different treatments by ELISA. There was significant degradation if saliva samples were stored at RT without any treatment. After 3 days, there was only 71.72 ⁇ 18% left when compared to positive control. If the saliva samples were kept a 4° C. with protease inhibitors, more than 85 ⁇ 12% of this protein could be detected in saliva and there was no significant change from positive control. In the saliva samples stored at RT with protease inhibitors, ⁇ -actin was found to be stable for only 3 days. When saliva samples were stored at 4° C. with protease inhibitor ⁇ -actin was found stable for about 1 month without significant degradation.
  • Amylase is the most abundant protein in saliva and greatly affects the stability of other salivary proteins. After removing amylase from saliva, salivary proteins became more stable.
  • the SDS-PAGE images of salivary proteins with and without amylase depletions are shown in FIGS. 9A and B.
  • FIGS. 9D and E The western blot of ⁇ -actin in saliva after stored for 7 days also demonstrated that it became more stable after amylase removal ( FIGS. 9D and E). If 20% ethanol was added, the stabilization efficiency for ⁇ -actin was better.
  • LC-MS/MS was run for the protein identification in the 4 bands of FIG. 9B lane RT.
  • band a three proteins were identified, including desmoplakin, deleted in malignant brain tumors 1 protein and syndecan-binding protein 2.
  • band b 7 proteins were found (mucin-7, tetra-peptide repeat homeobox protein 1, bactericidal/permeability-increasing protein-like 1, lactotransferrin, peroxisome proliferator-activated receptor gamma coactivator-related protein 1, alpha-2-macroglobulin, and polymeric immunoglobulin receptor).
  • FIG. 11A The western blot of ⁇ -actin with different treatments was shown in FIG. 11A . Their corresponding quantifications were shown in FIG. 11B .
  • the results showed that there was significant ⁇ -actin degradation at RT after day 3, 7 and 14 when compared to ⁇ 80° C.
  • protease inhibitor cocktail tablets used in this investigation were designed to inhibit a broad spectrum of serine, cysteine and metalloproteases as well as calpains (Chevalier et al., Proteomics 3:13 (2007)). Microbes may also generate some metabolites that can change the composition of human salivary proteome. RNA may interact with proteins and become stable (Palanisamy et al., J. Dent. Res. 87:772 (2008)). The storage temperature will also change the activity of different proteases, which will alter the stability of different proteins. By considering all these factors, salivary proteome is facing a huge risk of being digested or changed under different circumstances.
  • salivary proteins The efficiency of different methods was evaluated by testing selected protein targets. In order to properly stabilize salivary proteins, the activity of salivary proteases should be inhibited. Otherwise, as shown in FIG. 9A , salivary proteins will degrade quickly.
  • saliva sample In order to lower the metabolism of microbes, saliva sample should be kept at ⁇ 80° C.
  • Protease inhibitors were added to hinder protein degradation because saliva samples without any treatment will be digested very quickly, although the salivary protein concentrations were significantly lower than the positive control after 30 days at RT.
  • the data provided herein show that the addition of protease inhibitors and storage at 4° C. could effectively stabilize this protein for approximately two weeks. However, saliva samples could only be stabilized at RT for 3 days without significant change by adding protease inhibitors.
  • Subjects were asked to refrain from eating, drinking, smoking, and oral hygiene activities for at least 2 hours prior to collection.
  • Whole unstimulated saliva was then collected using the Oasis saliva collector “Super ⁇ SAL” ( FIG. 13 ) for about 10-15 min.
  • the collected saliva was then processed for respective molecular constituent (DNA, Protein and RNA) stabilization and storage.
  • the collection tubes were pre-loaded with specific stabilizers for protein, RNA and DNA. All samples can be transported and stored at room temperature.
  • the collected saliva is pushed through a barrel where there is a filtration unit (Millipore MGGF filter, 5 ⁇ m hydrophilic PVDF membrane) at the sample filtration end serving to remove cells, microbes and debris.
  • a filtration unit Micropore MGGF filter, 5 ⁇ m hydrophilic PVDF membrane
  • Half of the volume of the saliva filtrate is stored in a microfuge tube at room temperature for downstream applications including direct saliva transcriptome analysis. This sample was maintained at room temperature.
  • Subjects will be asked to refrain from eating, drinking, smoking, and oral hygiene activities for at least 2 hours prior to collection.
  • Whole unstimulated saliva will then be collected using an apparatus for the collection of saliva comprising a sample collection pad, a receiving device, and a filter connected to the receiving device.
  • the filter is a 5 ⁇ m hydrophilic membrane that filters out cells and microorganisms.
  • the filtered sample (1-2 ml) that is free from cells, microbes, and debris will be aliquoted into two microfuge collection tubes.
  • the first tube will have a 20% ethanol solution and the second tube will be free of ethanol. All collection activities will be conducted at ambient temperatures.
  • the filtered sample collected in the first tube having a 20% ethanol solution will be stored at room temperature for up to two weeks for downstream applications.
  • the filtered sample for protein analysis will have the protein concentration measured, and the sample will be used for SDS-PAGE and western blot analyses.
  • the saliva proteins will be run and transferred to a protein membrane.
  • the membrane containing the protein will be incubated with primary antibody and then secondary antibody. In-gel trypsin digestion and mass spectrometry will then be used to identify extracellular saliva proteins.
  • the filtered sample collected in the second tube without ethanol will be stored at room temperature for up to ten weeks for downstream applications, including direct saliva transcriptome analysis.
  • the filtered samples will then be treated with DNase.
  • RT-qPCR will then be used to analyze mRNA expression levels of extracellular saliva mRNAs.
  • the expression levels of the salivary transcripts will be detected using standard procedures of raw quantification cycle (Cq) values.
  • Cq raw quantification cycle
  • This example describes dual analysis of protein and nucleic acids collected from saliva samples by any person that is not required to be a specially trained technician. The samples will be collected and aliquoted for both protein and nucleic analysis, and subsequently stored at room temperature prior to analysis.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • General Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Surgery (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medical Informatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Provided herein is an all-in-one saliva collection apparatus that collects saliva to allow for the filtration of saliva in order to separate saliva components, such as extracellular proteins and nucleic acids that are not present in intact cells, from the intact cells and debris remaining in the extracted sample. The filtered saliva samples can be aliquoted into two fractions for protein and/or nucleic acid analysis. The present invention further describes long term storage at ambient temperatures of filtered salivary nucleic acids, and long term storage at ambient temperatures of filtered salivary proteins added to an ethanol solution. The filtered cell-free saliva samples have diagnostic usefulness.

Description

    CROSS-REFERENCES TO RELATED APPLICATIONS
  • The present application claims priority to U.S. Ser. No. 61/515,169, filed Aug. 4, 2012, herein incorporated by reference in its entirety.
    • STATEMENT OF GOVERNMENT RIGHTS
  • This invention was made with Government support under Grant No. CA0126733 awarded by the National Institutes of Health. The Government has certain rights in this invention.
    • FIELD OF THE DISCLOSURE
  • The present disclosure relates to an apparatus and methods for the analysis of protein and nucleic acids present in cell-free samples of saliva.
    • BACKGROUND OF THE INVENTION
  • Interest in using saliva as a diagnostic tool for disease detection and health surveillance is increasing due to its noninvasive accessibility, cost-effectiveness, easy sample collection and processing, and accumulating scientific rationale (Yan et al., Proteomics Clin. Appl. 3:116 (2009); Lee and Wong, Am J. Dent. 22:241-8 (2009)). Saliva has been used to detect, for example, caries risk, peridontitis, oral cancer, breast cancer, lung cancer, Sjögren's syndrome, salivary gland disease and infectious diseases such as hepatitis, HIV, and HCV. Saliva is therefore an attractive diagnostic sample alternative for blood, serum, or plasma.
  • Saliva is ideal for nucleic acid analysis. The human salivary transcriptome in cell-free saliva was first discovered in 2004 by use of microarray technology (Li et al, J. Dent. Res. 83:199-203 (2004)). Investigations into the characteristics of salivary RNA followed, which led to the development of salivary transcriptomics as a research focus. (Park et al., Clin. Chem 52:988-94 (2006); Park et al. Arch. Oral. Biol., 52:30-5 (2007)).
  • Saliva is additionally ideal for proteomic analysis. Profiling proteins in saliva over the course of disease progression can reveal biomarkers indicative of different stages of diseases, which can be useful in early detection and/or medical diagnosis (Hu et al., Proteomics 6:6326 (2006)). Proteomics is widely envisioned as a unique and powerful approach to biomarker development. As proteomic technologies continue to mature, proteomics has the great potential for salivary proteomic biomarker development and further clinical applications (Xiao and Wong, Bioinformation 5:294 (2011); Zhang et al, Mol. Diagn. Ther. 13:245 (2009)).
  • However, current methods for the extraction of nucleic acids and protein from saliva require the saliva sample to be processed immediately after collection requiring special instrumentation and trained personnel. For example, current standard procedures for salivary transcriptomic diagnostics require mRNA isolation, which is time-consuming and labor-intensive. In addition, operator differences increase as procedural complexity increases. Although several automated devices are commercially available to enhance mRNA isolation efficiency (e.g., KING FISHER<QIACUBE, and MAXWELL 16), throughput is still limited by the number of samples processed per run. Furthermore, particular care is required when working with RNA because of its inherent instability and the ubiquitous presence of RNases. Likewise, current standard procedures for salivary proteomic diagnostics require the addition of protease inhibitors to prevent proteolysis. As a result, current methods for transcriptomic and proteomic diagnostics require the addition of nucleic acid and protein stabilizers to be added to saliva samples followed by storage at −80° C.
  • The ability to analyze saliva to monitor health and disease is a highly desirable goal for oral health promotion and research. In order to fully realize the diagnostic and research uses of saliva as a source of biomarkers, systems for collection, handling, and room-temperature storage of saliva by non-professionals in a user friendly integrated point-of-care collection system are desirable.
    • BRIEF SUMMARY OF THE INVENTION
  • Saliva is an ideal translational research tool and diagnostic medium and is being used in unique ways to provide molecular biomarkers for a variety of oral and systemic diseases and conditions. The ability to analyze saliva to monitor health and disease is highly desirable for oral health promotion and research. Saliva has been used to detect caries risk, periodontitis, oral cancer, breast cancer, salivary gland disease, and infectious diseases such as hepatitis, HIV, and HCV. Measurement of salivary analytes requires optimal collection, processing and storage procedures and conditions.
  • In an embodiment, a method for stabilizing RNA and protein samples isolated from a saliva sample is provided. The method includes a) collecting a saliva sample from a subject; b) filtering the saliva sample to produce a filtered sample that is free of cells; c) collecting the filtered sample in at least a first and a second receiving device; d) adding an alcohol solution to the first receiving device to produce an alcohol-containing filtered sample comprising a protein sample, with the proviso that alcohol is not added to the second receiving device to produce an alcohol-free filtered sample comprising a nucleic acid sample; wherein the protein sample and the nucleic acid sample are stabilized for at least 3 days when stored at 25 degrees Celsius; and e) performing an analysis on the filtered sample collected in the first and second receiving devices comprising one or more of: a protein analysis on the alcohol-containing filtered sample or a nucleic acid analysis on the alcohol-free filtered sample. In a further embodiment, in accordance with any of the above embodiments or in combination with any of the above embodiments, the nucleic acid is DNA. In a further embodiment, in accordance with any of the above embodiments or in combination with any of the above embodiments, the nucleic acid analysis is polymerase chain reaction (PCR). In a further embodiment, in accordance with any of the above embodiments or in combination with any of the above embodiments, the nucleic acid is RNA. In a further embodiment, in accordance with any of the above embodiments or in combination with any of the above embodiments, the nucleic acid analysis is RT-PCR. In a further embodiment, in accordance with any of the above embodiments or in combination with any of the above embodiments, the RT-PCR is reverse transcription quantitative real-time PCR (RT-qPCR). In a further embodiment, in accordance with any of the above embodiments or in combination with any of the above embodiments, the ethanol solution comprises 20% ethanol. In a further embodiment, in accordance with any of the above embodiments or in combination with any of the above embodiments, the ethanol solution comprises 15-25% ethanol. In a further embodiment, in accordance with any of the above embodiments or in combination with any of the above embodiments, the ethanol solution comprises 5-35% ethanol. In a further embodiment, in accordance with any of the above embodiments or in combination with any of the above embodiments, the protein analysis comprises western blot, mass spectrometry protein identification, or ELISA. In a further embodiment, in accordance with any of the above embodiments or in combination with any of the above embodiments, the filtered sample is stored at ambient temperature. In a further embodiment, in accordance with any of the above embodiments or in combination with any of the above embodiments, the filtered sample is stored at ambient temperature for at least two weeks without more than 50% degradation of proteins or nucleic acids present in the filtered sample. In a further embodiment, in accordance with any of the above embodiments or in combination with any of the above embodiments, the filtered sample is stored at ambient temperature for at least two weeks without more than 25% degradation of proteins or nucleic acids present in the filtered sample. In a further embodiment, in accordance with any of the above embodiments or in combination with any of the above embodiments, the filtered sample is stored at ambient temperature for at least ten weeks without more than 50% degradation of proteins or nucleic acids present in the filtered sample. In a further embodiment, in accordance with any of the above embodiments or in combination with any of the above embodiments, the filtered sample is stored at ambient temperature for at least ten weeks without more than 25% degradation of proteins or nucleic acids present in the filtered sample. In a further embodiment, in accordance with any of the above embodiments or in combination with any of the above embodiments, the filter is selected from the group consisting of a 0.22 μm, 0.45 μm and 5.0 μm hydrophilic membrane. In a further embodiment, in accordance with any of the above embodiments or in combination with any of the above embodiments, the filter is a 0.22 μm hydrophilic membrane.
  • In another embodiment, an apparatus for the collection of saliva samples for biomarker detection is provided. In a further embodiment, in accordance with any of the above embodiments or in combination with any of the above embodiments, the apparatus comprises a sample collection pad, a filter, two or more receiving devices, wherein the receiving devices are selected from an mRNA collection tube, a polypeptide collection tube, and a DNA collection tube, wherein the polypeptide collection tube comprises an ethanol solution, and the DNA collection tube comprises a DNA stabilizer, wherein the filter is operably connected to the receiving devices. In a further embodiment, in accordance with any of the above embodiments or in combination with any of the above embodiments, the filter is selected from the group consisting of a 0.22 μm, 0.45 μm or 5.0 μm hydrophilic membrane. In a further embodiment, in accordance with any of the above embodiments or in combination with any of the above embodiments, the filter is a 0.22 μm hydrophilic membrane. In a further embodiment, in accordance with any of the above embodiments or in combination with any of the above embodiments, a method of using the apparatus is provided. The method includes inserting the sample collection pad into the oral cavity for sufficient time to moisten the sample collection pad, inserting the collection pad into the receiving tube, applying sufficient force to cause the materials collected in the collection pad to pass through the filter thereby forming a filtered sample, and collecting the filtered sample into one or more receiving devices.
  • In another embodiment, a method for stabilizing RNA and protein samples isolated from a saliva sample is provided. The method includes a) collecting a saliva sample from a human subject; b) filtering the saliva sample using a 0.22 μm to 5.0 μm hydrophilic membrane to produce a filtered sample that is free of cells; c) collecting the filtered sample in at first and a second receiving device; d) adding an ethanol solution to the first receiving device to produce a 20% ethanol-containing filtered sample comprising a protein sample, with the proviso that alcohol is not added to the second receiving device to produce an alcohol-free filtered sample comprising a nucleic acid sample; wherein the protein sample and the nucleic acid sample are stabilized for at least 3 days when stored at 25 degrees Celsius. In a further embodiment, in accordance with any of the above embodiments or in combination with any of the above embodiments, the method further comprises the step of (e) performing an analysis on the filtered samples collected in the first and second receiving devices comprising one or more of: a protein analysis on the ethanol-containing filtered sample or a nucleic acid analysis on the alcohol-free filtered sample. In a further embodiment, in accordance with any of the above embodiments or in combination with any of the above embodiments, the protein sample is stabilized for at least 2 weeks when stored at 25 degrees Celsius. In a further embodiment, in accordance with any of the above embodiments or in combination with any of the above embodiments, the nucleic acid sample is stabilized for at least 10 weeks when stored at 25 degrees Celsius. In some embodiments, the ethanol solution comprises 15-25% ethanol. In a further embodiment, in accordance with any of the above embodiments or in combination with any of the above embodiments, the ethanol solution comprises 5-35% ethanol. In a further embodiment, in accordance with any of the above embodiments or in combination with any of the above embodiments, the hydrophilic membrane in 0.22 μm.
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 illustrates a schematic diagram of the experimental design of Example 1.
  • FIG. 2 illustrates the effect of DNA removal by the described DNase treatment procedures as demonstrated using human cell genomic DNA (300 μg/ml) as template. Solid bars represent GAPDH, white bars represent ACTB, and striped bars represent RPS9.
  • FIG. 3 illustrates expression levels of 3 SIRG mRNAs analyzed by standard procedures and the DSTA method at day 0.
  • FIG. 4 illustrates expression levels of 3 SIRG mRNAs measure during 10 weeks of storage at ambient temperature without stabilizing reagent.
  • FIG. 5 illustrates box-and-whisker plots showing the Cq value distributions of 90 clinical samples used in the validation study of OSCC salivary transcripts. The results of each transcript were displayed individually in (A) H3F3A; (B) IL1B; (C) IL8; (D) OAZi; (E) SAT1; (F) DUSP1, and (G) S100P. Each transcript was detected in 27 OSCC and 63 normal subjects by standard and streamlined procedures at Day 0 and Week 10 (DSTA method only), which were represented by 1-6 on X axis: 1: Normal subjects assayed by standard procedures; 2: OSCC subjects assayed by standard procedures; 3: Normal subjects assayed by the SDTA method of Day 0; 4: OSCC subjects assayed by the DSTA method at Day 0; 5: Normal subjects assayed by the DSTA method at Week 10; and 6: OSCC subjects assayed by the DSTA method at Week 10. Y axis is represented by raw Cq value in each plot.
  • FIG. 6 illustrates (A) ROC curves for 7 OSCC salivary transcripts that was each detected by standard procedures, (B) ROC curves for 7 OSCC salivary transcripts that each was detected by the DSTA at day 0, and (C) ROC curves for 7 OSCC salivary transcripts that each was detected by the DSTA at week 10.
  • FIG. 7 illustrates a schematic diagram of the saliva sample collection and experimental design of Example 2.
  • FIG. 8 illustrates ELISA analysis of saliva β-actin: RT+R: RT with protease inhibitors; 4° C.+R: 4 degree with protease inhibitors (n=5) (*: p<0.05).
  • FIG. 9 illustrates SDS-Page for saliva proteins without (A) and with (B) amylase depletion, samples were stored for 3 days with corresponding treatment (C) Relative quantification of the labeled 4 bands (D) The western blot of β-actin after 7 days (E) The quantification data for the western blot in (D) (n=3). All quantification was normalized by the corresponding bands in the positive control. RT w/E: room temperature with adding 20% ethanol (a) without amylase depletion; (b) with amylase depletion.
  • FIG. 10 illustrates Protein stabilization by denaturing. (A) Western blot of β-actin, RT w/B: RT with boiling, RT w/e: RT with 20-time volumes ethanol added (B) The quantification data for western blot in (A) (n=5).
  • FIG. 11 illustrates western blot of β-actin (A) with and without adding ethanol at day 3, day 7 and day 14. The quantification data is shown in dot plot (B) (n=8). RT w/E: room temperature with 20% ethanol added.
  • FIG. 12 illustrates ELISA of IL1β in saliva samples (n=10) at different conditions. (A) Stored for 7 days (B) Stored for 14 days (C) Stored for 30 days. RT w/E: room temperature with 20% ethanol added.
  • FIG. 13 illustrates depicts a scheme of saliva collection, processing, stabilization and storage (SCPSS) as described in Example 3. Provided are a syringe, absorbent pad, filter, tubes and stabilizers. The collection scheme of various biomarkers is shown.
    •  DETAILED DESCRIPTION OF THE INVENTION Introduction
  • Human saliva contains an array of analytes (proteins, mRNA, and DNA) that can be used as biomarkers for translational and clinical applications. For example, saliva can be used to detect, caries risk, peridontitis, oral cancer, breast cancer, lung cancer, Sjögren's syndrome, salivary gland disease and infectious diseases such as hepatitis, HIV, and HCV.
  • A value of using saliva as a source of biomarkers is the ease of sampling and high subject compliance for sample collection. Presence of RNAs and protein in the cell-free fluid phase portion of saliva was confirmed by the procedures described extensively in the Examples. However, current methods for the extraction of nucleic acids and protein from saliva require the saliva sample to be processed immediately after collection using special instrumentation and trained personnel, the addition of nucleic acid and protein stabilizers, and storage at −80° C.
  • The ability to provide a user friendly and easy to use collector apparatus for major salivary diagnostic analytes is of interest. The present invention provides methods and an apparatus for the collection of saliva and saliva biomarkers. The methods can be carried out by non-professionals in a user friendly integrated point-of-care collection system that allows storage and shipment at room temperature without the addition of commonly used nucleic acid and protein stabilizers.
    • Definitions
  • Unless otherwise noted, the technical terms used herein are according to conventional usage as understood by persons skilled in the art. Definitions of common terms in molecular biology may be found in standard texts (e.g. Benjamin Lewin, Genes V, published by Oxford University Press, 1994 (ISBN 0-19854287-9); Kendrew et al. (eds.), The Encyclopedia of Molecular Biology, published by Blackwell Science Ltd, 1994 (ISBN 0-632-02182-9); and Robert A. Meyers (ed.), Molecular Biology and Biotechnology: a Comprehensive Desk Reference, published by VCH Publishers, Inc., 1995 (ISBN 1-56081-569-8)).
  • A “saliva sample” refers to samples derived from saliva from an animal that produces saliva. Saliva is a component of oral fluid produced in most animals.
  • A “filtered sample” refers to a saliva sample that has been processed to remove cells by separating the cell-phase and the fluid phase of saliva. A filtered sample can have more than 50%, more than 75%, more than 95%, or a 100% removal of cells. A sample is filtered to avoid mechanical rupture of cellular elements that could contribute to the detection of unwanted analytes in the cell-free phase. A filtered sample can further exclude extraneous substances, including but not limited to, food debris.
  • The term “alcohol solution” refers to any solution containing an alcohol such as methanol, isopropyl alcohol, and ethanol. An alcohol solution can contain, for example, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, or 100% alcohol, e.g., ethanol. The term “alcohol-containing filtered sample” refers to a cell free saliva sample comprising an alcohol, e.g., an ethanol solution, as described herein.
  • The term “alcohol-free filtered sample” refers to a cell free saliva sample that is at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% free of alcohol, including but not limited to, isopropyl alcohol, methanol, or ethanol.
  • The term “analysis” as used herein refers to any quantitative or qualitative examination or measurement of saliva components. Non-limiting examples are analyses that determine the presence or absence of nucleic acids or proteins; over or under expression of nucleic acids or proteins; or a genomic, transcriptomic, or proteomic examination of a saliva sample.
  • The term “collection apparatus” refers to any apparatus that can be used to collect saliva. As used herein, a collection apparatus includes a sample collection pad as described herein, a filter that is capable of separating cells from a sample as described herein, and a receiving device that is capable of receiving the filtered sample as described herein.
  • The term “collection pad” refers to any material that is suitable for collection of saliva. Examples can include, but are not limited to, nitrocellulose, cellulose acetate, polyethersulfur fabric, cellulose fiber such as paper strips or cotton, nylon, gel foam, fiber glass, polycarbonate, polyproplene, acetate, rayon, polyester absorbent pad, or other synthetic materials capable of collecting saliva.
  • The term “filter” refers to any filter capable of separating cells from a saliva sample. Exemplary filters can include, but are not limited to, cellulose fiber matrix, hydrophilic filters, such as those based on polyvinylidene fluoride membrane, or filters based on polypropylene membrane. Filters can have micropores that are a wide variety of sizes, including, but not limited to, 0.22 μm, 0.45 μm and 5.0 μm. The term “filtering” refers to the application of a liquid sample containing cells, e.g. a saliva sample, to a membrane filter. Filtering is the process of removing cells and/or parts of cells from excess fluid in a liquid sample by passing the sample through a microporous membrane filter.
  • The phrase “free of cells” refers to a sample solution that has been filtered in accordance with the methods of the present invention such that the sample solution is completely or substantially cell-free.
  • The term “degradation” refers to, for example, the proteolytic cleavage of proteins into smaller peptides and amino acids; or the catalysis of nucleic acids into smaller components. Degradation as used herein results in proteins and nucleic acids having compromised gene expression and clinical utilities.
  • The term “receiving device” refers to any device capable of collecting a filtered sample. Receiving devices can include, but are not limited to, devices formed wholly or partially from plastic, such as polypropylene, polystyrene, polycarbonate, polyurethane, or polyethylene, polycarbonate, polytetrafluoroethylene, enamel, nylon, ceramic or any combination thereof, or from glass and/or metallic materials. Receiving devices can be, for example, snap cap, screw cap, and loop-cap microcentrifuge tubes.
  • The term “ambient temperature” is the temperature of the surrounding environment, which generally refers to room temperature in a clinical setting. Ambient temperature is generally between 20 and 25 degrees Celsius.
  • The term “extracellular” as used herein refers to fluidic space outside the plasma membranes of cells. The composition of the extracellular space can include proteins, nucleic acids, lipids, hormones, microbial product, etc.
  • The term “stabilizing” or “stabilization” refers to any effect of the methods according to the present invention resulting in the stabilization of the structure and/or activity of a biomolecule, the elongation of the shelf-life of a biomolecule and/or the protection of a biomolecule against stress. This results in a biological activity of the biomolecule which is retained to a significant degree. Exemplary stabilizations can be nucleic acids or proteins that are stabilized for 2 to 10 weeks or more at room temperature.
  • The term “nucleic acid” refers to deoxyribonucleotides or ribonucleotides and polymers thereof in either single- or double-stranded form, and complements thereof. The term refers to all forms of nucleic acids (e.g., gene, pre-mRNA, mRNA) and their polymorphic variants, alleles, mutants, and interspecies homologs. The term nucleic acid is used interchangeably with gene, cDNA, mRNA, oligonucleotide, and polynucleotide. The term encompasses nucleic acids that are naturally occurring or recombinant. Nucleic acids can (1) code for an amino acid sequence that has greater than about 60% amino acid sequence identity, 65%, 70%, 75%, 80%, 85%, 90%, preferably 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% or greater amino acid sequence identity, preferably over a region of at least about 25, 50, 100, 200, 500, 1000, or more amino acids, to a polypeptide encoded by a referenced nucleic acid or an amino acid sequence described herein; (2) specifically bind to antibodies, e.g., polyclonal antibodies, raised against an immunogen comprising a referenced amino acid sequence, immunogenic fragments thereof, and conservatively modified variants thereof; (3) specifically hybridize under stringent hybridization conditions to a nucleic acid encoding a referenced amino acid sequence, and conservatively modified variants thereof, (4) have a nucleic acid sequence that has greater than about 95%, preferably greater than about 96%, 97%, 98%, 99%, or higher nucleotide sequence identity, preferably over a region of at least about 25, 50, 100, 200, 500, 1000, or more nucleotides, to a reference nucleic acid sequence.
  • The terms “polypeptide,” “peptide” and “protein” are used interchangeably herein to refer to a polymer of amino acid residues. The terms apply to amino acid polymers in which one or more amino acid residue is an artificial chemical mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers and non-naturally occurring amino acid polymer.
  • The term “amino acid” refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function in a manner similar to the naturally occurring amino acids. Naturally occurring amino acids are those encoded by the genetic code, as well as those amino acids that are later modified, e.g., hydroxyproline, γ-carboxyglutamate, and O-phosphoserine. Amino acid analogs refers to compounds that have the same basic chemical structure as a naturally occurring amino acid, e.g., an a carbon that is bound to a hydrogen, a carboxyl group, an amino group, and an R group, e.g., homoserine, norleucine, methionine sulfoxide, methionine methyl sulfonium. Such analogs have modified R groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as a naturally occurring amino acid. Amino acid mimetics refers to chemical compounds that have a structure that is different from the general chemical structure of an amino acid, but that functions in a manner similar to a naturally occurring amino acid. Amino acids may be referred to herein by either their commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Nucleotides, likewise, may be referred to by their commonly accepted single-letter codes.
  • The phrase “specifically (or selectively) binds” when referring to a protein, nucleic acid, antibody, or small molecule compound refers to a binding reaction that is determinative of the presence of the protein or nucleic acid, such as the differentially expressed genes of the present invention, often in a heterogeneous population of proteins or nucleic acids and other biologics. In the case of antibodies, under designated immunoassay conditions, a specified antibody may bind to a particular protein at least two times the background and more typically more than 10 to 100 times background. Specific binding to an antibody under such conditions requires an antibody that is selected for its specificity for a particular protein. For example, polyclonal antibodies can be selected to obtain only those polyclonal antibodies that are specifically immunoreactive with the selected antigen and not with other proteins. This selection may be achieved by subtracting out antibodies that cross-react with other molecules. A variety of immunoassay formats may be used to select antibodies specifically immunoreactive with a particular protein. For example, solid-phase ELISA immunoassays are routinely used to select antibodies specifically immunoreactive with a protein (see, e.g., Harlow & Lane, Antibodies, A Laboratory Manual (1988) for a description of immunoassay formats and conditions that can be used to determine specific immunoreactivity).
    • Nucleic Acid Analysis
  • Embodiments described herein include a streamlined, ambient-temperature processing, stabilization, and storage of nucleic acids derived from saliva. Direct saliva transcriptome and genome analyses using cell-free saliva supernatant instead of isolated nucleic acids, which include the processing, stabilization, and storage of saliva samples, as described herein, can be performed at ambient temperature without stabilization agents. In some embodiments, stabilization agents can be included. In some embodiments, alcohol can be included.
  • Profiling salivary nucleic acids over the course of disease progression can reveal potential biomarkers indicative of different stages of disease, which can be useful in early detection of disease. Nucleic acid stabilization requiring extremely low temperatures or nucleic acid stabilization chemicals can be impractical for field applications or daily clinical operations. Furthermore, nucleic acid stabilizers can affect downstream analyses. Described herein is the extraction of extracellular nucleic acids that can be stored at ambient temperatures until needed for downstream applications, such as PCR, without the need for additional stabilization chemicals.
  • The nucleic acids of the present invention can be stored at room temperature for longer than 1 week, 2 weeks, 5 weeks, 10 weeks, or 25 weeks or more.
  • The methodology for preparing nucleic acids in a form that is suitable for detection following collection of the cell-free salivary sample is well known in the art. Such methods can include, but are not limited to, PCR, reverse transcriptase-PCR (RT-PCR), real-time PCR, reverse transcription quantitative real-time PCR (RT-qPCR), ligase chain reaction, strand displacement amplification (SDA), self-sustained sequence replication (3SR), or in situ PCR. Any suitable qualitative or quantitative methods known in the art for detecting specific nucleic acid (e.g., RNA or DNA) can be used. Nucleic acid can be detected by, for example, by reverse transcriptase-PCR, or in Northern blots containing poly A mRNA, and other methods well known in the art.
  • Applicable PCR amplification techniques are described in, e.g., Ausubel et al. and Innis et al., supra. General nucleic acid hybridization methods are described in Anderson, “Nucleic Acid Hybridization,” BIOS Scientific Publishers, 1999. For PCR, a temperature of about 36° C. is typical for low stringency amplification, although annealing temperatures may vary between about 32° C. and 48° C. depending on primer length. For high stringency PCR amplification, a temperature of about 62° C. is typical, although high stringency annealing temperatures can range from about 50° C. to about 65° C., depending on the primer length and specificity. Typical cycle conditions for both high and low stringency amplifications include a denaturation phase of 90° C.-95° C. for 30 sec-2 min., an annealing phase lasting 30 sec.-2 min., and an extension phase of about 72° C. for 1-2 min. Protocols and guidelines for low and high stringency amplification reactions are provided, e.g., in Innis et al., PCR Protocols, A Guide to Methods and Applications, Academic Press, Inc. N.Y. (1990).
  • Real time, quantitative reverse transcriptase PCR (RT-PCR), or reverse transcription quantitative real-time PCR (RT-qPCR) can be used to determine the presence of mutations. RNA extraction can be performed by any method know to those of skill in the art, e.g., methods involving proteinase K tissue digestion and alcohol-based nucleic acid precipitation, treatment with DNase to digest contaminating DNA, RNA purification using silica-gel-membrane technology, methods utilizing commercially available kits such as Trizol and RNeasy, or any combination thereof. Real time RT-PCR can be performed by any method known to those of skill in the art, e.g., Taqman real time PCR using Applied Biosystem assays.
  • Nucleic acid primers, or probes can be generated using the polynucleotide sequences disclosed herein. The probes are preferably at least about 12, 15, 16, 18, 20, 22, 24, or 25 nt fragments of a contiguous sequence of nucleic acid or polypeptide. The probes can be produced by, for example, chemical synthesis, PCR amplification, generation from longer polynucleotides using restriction enzymes, or other methods well known in the art.
  • Nucleic acid probes can be used as diagnostics wherein a biological sample to be analyzed, such as saliva, can be treated, if desired, to extract the nucleic acids contained therein. The resulting nucleic acid from the sample can be subjected to gel electrophoresis or other size separation techniques; alternatively, the nucleic acid sample can be dot blotted without size separation. The nucleic acids extracted from the sample are then treated with the labeled probe under hybridization conditions of suitable stringencies. The probes can be made completely complementary to the target nucleic acid or portion thereof (e.g., to all or a portion of a sequence encoding a target). Therefore, usually high stringency conditions are desirable in order to prevent or at least minimize false positives. However, conditions of high stringency should only be used if the probes are complementary to regions of the target which lack heterogeneity. The stringency of hybridization is determined by a number of factors during hybridization and during the washing procedure, including temperature, ionic strength, length of time, and concentration of formamide (Sambrook et al. (1989), “Molecular Cloning; A Laboratory Manual,” Second Edition (Cold Spring Harbor Press, Cold Spring Harbor, N.Y.)).
  • Nucleic acid probes, or alternatively nucleic acid from the samples, can be provided in solution for such assays, or can be affixed to a support (e.g., solid or semi-solid support). Examples of supports that can be used are nitrocellulose (e.g., in membrane or microtiter well form), polyvinyl chloride (e.g., in sheets or microtiter wells), polystyrene latex (e.g., in beads or microtiter plates, polyvinylidine fluoride, diazotized paper, nylon membranes, activated beads, and Protein A beads.
  • Non-PCR-based, sequence specific DNA amplification techniques can also be used with the invention to detect nucleic acids. An example of such techniques include, but is not necessarily limited to, the Invader assay (see, e.g., Kwiatkowski et al. Mol Diagn. 1999, 4:353-64. See also U.S. Pat. No. 5,846,717).
  • Nucleic acids can be detectably labeled. Exemplary detectable labels include, but are not limited to, radiolabels, fluorochromes, (e.g. fluorescein isothiocyanate (FITC), rhodamine, Texas Red, phycoerythrin, allophycocyanin, 6-carboxyfluorescein (6-FAM), 2′,7′-dimethoxy-4′,5′-dichloro-6-carboxyfluorescein, 6-carboxy-X-rhodamine (ROX), 6-carboxy-2′,4′,T,4,7-hexachlorofluorescein (HEX), 5-carboxyfluorescein (5-FAM) or N,N,N′,N′-tetramethyl-6-carboxyrho-damine (TAMRA)), radioactive labels, (e.g. .sup.32p, .sup.35S, and sup.3H), and the like. The detectable label can involve two stage systems (e.g., biotin-avidin, hapten-anti-hapten antibody, and the like).
  • Analysis of nucleic acid mutations derived from saliva samples can be performed using techniques known in the art including, without limitation, electrophoretic analysis or sequence analysis. Non-limiting examples of electrophoretic analysis include slab gel electrophoresis such as agarose or polyacrylamide gel electrophoresis, capillary electrophoresis, and denaturing gradient gel electrophoresis (DGGE). Other methods of nucleic acid analysis include, but is limited to, restriction analyses such as restriction-fragment-length-polymorphism detection based on allele-specific restriction-endonuclease cleavage (Kan and Dozy, Lancet ii:910-12 (1978)), hybridization with allele-specific oligonucleotide probes (Wallace et al., Nucl. Acids Res. 6:3543-3557 (1978)), including immobilized oligonucleotides (Saiki et al., PNAS 86:6230-6234 (1989)), oligonucleotide arrays (Maskos and Southern, Nucl. Acids Res. 21:2269-2270 (1993)), oligonucleotide-ligation assay (OLA) (Landegren et al., Science 241:1077 (1988)), allele-specific ligation chain reaction (LCR) (Barrany, PNAS 88:189-193 (1991)), gap-LCR (Abavaya et al. Nucl. Acids Res. 23:675-682 (1995)), single-strand-conformation-polymorphism detection (Orita et al., Genomics 5:874-879 (1983)), RNAase cleavage at mis-matched base-pairs (Myers et al., Science 230:1242 (1985)), cleavage of heteroduplex DNA, methods based on allele specific primer extension, genetic bit analysis (GBA) (Nikiforov et al., Nucl. Acids Res. 22:4167-4175 (1994)), in situ hybridization, Southern blot, Northern blot analysis, denaturing high performance liquid chromatography (DHPLC) (Kim et al., Genetic Testing 12:295-298 (2008)). Non-limiting examples of sequence analysis include Maxam-Gilbert sequencing, Sanger sequencing, capillary array DNA sequencing, thermal cycle sequencing (Sears et al., Biotechniques, 13:626-633 (1992)), solid-phase sequencing (Zimmerman et al., Methods Mol. Cell Biol., 3:39-42 (1992)), sequencing with mass spectrometry such as matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF/MS; Fu et al., Nat. Biotechnol., 16:381-384 (1998)), and sequencing by hybridization (Chee et al., Science, 274:610-614 (1996); Drmanac et al., Science, 260:1649-1652 (1993); Drmanac et al., Nat. Biotechnol., 16:54-58 (1998)), NGS (next-generation sequencing) (Chen et al., Genome Res. 18:1143-1149 (2008); Srivatsan et al. PloS Genet. 4:e1000139 (2008)), Polony sequencing (Porreca et al., Curr. Protoc. Mol. Biol. Chp. 7; Unit7.8 (2006), ion semiconductor sequencing (Elliott et al., J.Biomol Tech. 1:24-30 (2010), DNA nanoball sequencing (Kaji et al., Chem Soc Rev 39:948-56 (2010), single molecule real-time sequencing (Flusberg et al., Nat. Methods 6:461-5 (2010), or nanopore DNA sequencing (Wanunu, Phys Life Rev 9:125-58 (2012).
  • Probes (or sample nucleic acid) can be provided on an array for detection following saliva extraction. Arrays can be created by, for example, spotting polynucleotide probes onto a substrate (e.g., glass, nitrocellulose, and the like) in a two-dimensional matrix or array. The probes can be bound to the substrate by either covalent bonds or by non-specific interactions, such as hydrophobic interactions. Samples of polynucleotides can be detectably labeled (e.g., using radioactive or fluorescent labels) and then hybridized to the probes. Double stranded polynucleotides, comprising the labeled sample polynucleotides bound to probe polynucleotides, can be detected once the unbound portion of the sample is washed away. Techniques for constructing arrays and methods of using these arrays are described in EP 799 897; WO 97/29212; WO 97/27317; EP 785 280; WO 97/02357; U.S. Pat. No. 5,593,839; U.S. Pat. No. 5,578,832; EP 728 520; U.S. Pat. No. 5,599,695; EP 721 016; U.S. Pat. No. 5,556,752; WO 95/22058; and U.S. Pat. No. 5,631,734. Arrays are particularly useful where, for example a single sample is to be analyzed for the presence of two or more nucleic acid target regions, as the probes for each of the target regions, as well as controls (both positive and negative) can be provided on a single array. Arrays thus facilitate rapid and convenience analysis.
    • Protein Analysis
  • Embodiments described herein include a streamlined, ambient-temperature processing, stabilization, and storage of proteins derived from saliva. Direct saliva proteomic analyses using cell-free saliva supernatant instead of isolated proteins, which include the processing, stabilization, and storage of saliva samples, as described herein, can be performed at ambient temperature.
  • Profiling saliva proteins over the course of disease progression can reveal potential biomarkers indicative of different stages of disease, which can be useful in early detection of disease. Protein stabilization requiring extremely low temperatures or protein stabilization chemicals can be impractical for field applications or daily clinical operations. Furthermore, protein stabilizers can affect downstream analyses. In some embodiments, protein stabilizers can be used. In other embodiments, protein stabilizers are not used. In other embodiments, ethanol can be used to stabilize the salivary proteins of the present invention.
  • Described herein is further the addition of alcohol to increase the stability of cell-free saliva samples at ambient temperature. Without being bound by theory, alcohol could replace ordered water molecules around exposed hydrophobic groups, which surround the non-polar side chins of the proteins and thus increase the stability of salivary proteins. Alcohol can include, but it not limited to, ethanol. Alcohol can be added, for example, at concentrations of 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95% alcohol. Alcohol can be added, for example, at concentrations of 25-35%, 20-40%, 15-45%, 10-50%, 5-50%.
  • The nucleic acids of the present invention can be stored at room temperature for longer than 1 week, 2 weeks, 5 weeks, 10 weeks, or 25 weeks or more.
  • The methodology for preparing protein in a form that is suitable for detection following collection of the cell-free salivary sample is well known in the art. Extracellular protein can be purified to substantial purity by standard techniques, including selective precipitation with such substances as ammonium sulfate; column chromatography, immunopurification methods, and others (see, e.g., Scopes, Protein Purification: Principles and Practice (1982); U.S. Pat. No. 4,673,641; Ausubel et al, supra; and Sambrook et al., supra).
  • The molecular weight of the protein can be used to isolate it from proteins of greater and lesser size using ultrafiltration through membranes of different pore size (for example, Amicon or Millipore membranes). As a first step, the protein mixture is ultrafiltered through a membrane with a pore size that has a lower molecular weight cut-off than the molecular weight of the protein of interest. The retentate of the ultrafiltration is then ultrafiltered against a membrane with a molecular cut off greater than the molecular weight of the protein of interest. The recombinant protein will pass through the membrane into the filtrate. The filtrate can then be chromatographed.
  • The protein can also be separated from other proteins on the basis of its size, net surface charge, hydrophobicity, and affinity for ligands or substrates using column chromatography. In addition, antibodies raised against proteins can be conjugated to column matrices and the proteins immunopurified. All of these methods are well known in the art. It will be apparent to one of skill that chromatographic techniques can be performed at any scale and using equipment from many different manufacturers (e.g., Pharmacia Biotech).
  • Antibody reagents can be used in assays to detect proteins in saliva samples using any of a number of immunoassays known to those skilled in the art. Immunoassay techniques and protocols are generally described in Price and Newman, “Principles and Practice of Immunoassay,” 2nd Edition, Grove's Dictionaries, 1997; and Gosling, “Immunoassays: A Practical Approach,” Oxford University Press, 2000. A variety of immunoassay techniques, including competitive and non-competitive immunoassays, can be used. (See, e.g., Self et al., Curr. Opin. Biotechnol 7:60-65 (1996)). The term immunoassay encompasses techniques including, without limitation, enzyme immunoassays (EIA) such as enzyme multiplied immunoassay technique (EMIT), enzyme-linked immunosorbent assay (ELISA), IgM antibody capture ELISA (MAC ELISA), and microparticle enzyme immunoassay (META); immunohistochemical assay, capillary electrophoresis immunoassays (CEIA); radioimmunoassays (RIA); immunoradiometric assays (IRMA); fluorescence polarization immunoassays (FPIA); and chemiluminescence assays (CL). If desired, such immunoassays can be automated. Immunoassays can also be used in conjunction with laser induced fluorescence. (See, e.g., Schmalzing et al., Electrophoresis, 25 18:2184-93 (1997); Bao, J Chromatogr. B. Biomed. Sci., 699:463-80 (1997)). Liposome immunoassays, such as flow-injection liposome immunoassays and liposome immunosensors, are also suitable for use in the present invention. (See, e.g., Rongen et al., J. Immunol. Methods, 204:105-133 (1997)). In addition, nephelometry assays, in which the formation of protein/antibody complexes results in increased light scatter that is converted to a peak rate signal as a function of the marker concentration, are suitable for use in the methods of the present invention. Nephelometry assays are commercially available from Beckman Coulter (Brea, Calif.; Kit #449430) and can be performed using a Behring Nephelometer Analyzer (Fink et al., J Clin. Chem. Clin. Biochem., 27:261-276 (1989)).
  • Specific immunological binding of an antibody can be detected directly or indirectly. A detectable moiety can be used (direct or indirect detection). A variety of detectable moieties are well known to those skilled in the art, and can be any material detectable by spectroscopic, photochemical, biochemical, immunochemical, electrical, optical or chemical means. Detectable moieties can be used, with the choice of label depending on the sensitivity required, ease of conjugation with the antibody, stability requirements, and available instrumentation and disposal provisions. Suitable detectable moieties include, but are not limited to, radionuclides, fluorescent dyes (e.g., fluorescein, fluorescein isothiocyanate (FITC), Oregon Green™, rhodamine, Texas red, tetrarhodimine isothiocynate (TRITC), Cy3, Cy5, etc.), fluorescent markers (e.g., green fluorescent protein (GFP), phycoerythrin, etc.), autoquenched fluorescent compounds that are activated by tumor-associated proteases, enzymes (e.g., luciferase, horseradish peroxidase, alkaline phosphatase, etc.), nanoparticles, biotin, digoxigenin, metals, and the like. Direct labels include fluorescent or luminescent tags, metals, dyes, radionucleodies, and the like, attached to the antibody. An antibody labeled with iodine-125 (1251) can be used. A chemiluminescence assay using a chemiluminescent antibody specific for nucleic acids or proteins is suitable for sensitive, non-radioactive detection of nucleic acids or protein levels. An antibody labeled with fluorochrome is also suitable. Examples of fluorochromes include, without limitation, DAPI, fluorescein, Hoechst 33258, R-phycocyanin, B-phycoerythrin, R-phycoerythrin, rhodamine, Texas red, and lissamine. Indirect labels include various enzymes well known in the art, such as horseradish peroxidase (HRP), alkaline phosphatase (AP), β-galactosidase, urease, and the like. A horseradish-peroxidase detection system can be used, for example, with the chromogenic substrate tetramethylbenzidine (TMB), which yields a soluble product in the presence of hydrogen peroxide that is detectable at 450 nm. An alkaline phosphatase detection system can be used with the chromogenic substrate p-nitrophenyl phosphate, for example, which yields a soluble product readily detectable at 405 nm. Similarly, a β-galactosidase detection system can be used with the chromogenic substrate o-nitrophenyl-β-D-galactopyranoside (ONPG), which yields a soluble product detectable at 410 nm. An urease detection system can be used with a substrate such as urebromocresol purple (Sigma Immunochemicals; St. Louis, Mo.). Other proteins capable of specifically binding immunoglobulin constant regions, such as protein A or protein G can also be used as a label agent. These proteins exhibit a strong non-immunogenic reactivity with immunoglobulin constant regions from a variety of species (see, e.g., Kronval et al., J. Immunol. 111:1401-1406 (1973); Akerstrom et al., J. Immunol. 135:2589-2542 (1985).
  • Western blot (immunoblot) analysis can be used to detect and quantify the presence of an antigen in the sample. The technique generally comprises separating sample proteins by gel electrophoresis on the basis of molecular weight, transferring the separated proteins to a suitable solid support, (such as a nitrocellulose filter, a nylon filter, or derivatized nylon filter), and incubating the sample with the antibodies that specifically bind the antigen. The anti-antigen antibodies specifically bind to the antigen on the solid support. These antibodies can be directly labeled or alternatively can be subsequently detected using labeled antibodies (e.g., labeled sheep anti-mouse antibodies) that specifically bind to the anti-antigen antibodies.
  • An ELISA method can be used as follows: (1) bind an antibody or antigen to a substrate; (2) contact the bound receptor with a fluid or tissue sample containing the virus, a viral antigen, or antibodies to the virus; (3) contact the above with an antibody bound to a detectable moiety (e.g., horseradish peroxidase enzyme or alkaline phosphatase enzyme); (4) contact the above with the substrate for the enzyme; (5) contact the above with a color reagent; (6) observe color change. The above method can be readily modified to detect presence of an antibody in the sample or a specific protein as well as a virus.
  • An antigen and/or a subject's antibodies to the virus can be detected utilizing a capture assay. Briefly, to detect antibodies in a sample, antibodies to an immunoglobulin, e.g., anti-IgG (or IgM) are bound to a solid phase substrate and used to capture the patient's immunoglobulin from serum. The antigen, or reactive fragments of the antigen, are then contacted with the solid phase followed by addition of a labeled antibody. The amount of specific antibody can then be quantitated by the amount of labeled antibody binding. A micro-agglutination test can also be used to detect the presence of an antigen in test samples. Briefly, latex beads are coated with an antibody and mixed with a test sample, such that the antigen in the tissue or body fluids that is specifically reactive with the antibody crosslink with the receptor, causing agglutination. The agglutinated antibody-virus complexes within a precipitate, visible with the naked eye or by spectrophotometer.
  • Competitive assays can also be adapted to provide for an indirect measurement of the amount of an antigen present in the sample. Briefly, serum or other body fluids from the subject is reacted with an antibody bound to a substrate (e.g. an ELISA 96-well plate). Excess serum is thoroughly washed away. A labeled (enzyme-linked, fluorescent, radioactive, etc.) monoclonal antibody is then reacted with the previously reacted antibody complex. The amount of inhibition of monoclonal antibody binding is measured relative to a control. Monoclonal antibodies (MABs) can also be used for detection directly in samples by IFA for MABs specifically reactive for the antibody-antigen complex.
  • A hapten inhibition assay is another competitive assay. In this assay the known antigen can be immobilized on a solid substrate. A known amount of anti-antigen antibody is added to the sample, and the sample is then contacted with the immobilized antigen. The amount of antibody bound to the known immobilized antigen is inversely proportional to the amount of antigen present in the sample. The amount of immobilized antibody can be detected by detecting either the immobilized fraction of antibody or the fraction of the antibody that remains in solution. Detection can be direct where the antibody is labeled or indirect by the subsequent addition of a labeled moiety that specifically binds to the antibody as described above.
  • Immunoassays in the competitive binding format can also be used for crossreactivity determinations. For example, an antigen can be immobilized to a solid support. Proteins can be added to the assay that competes for binding of the antisera to the immobilized antigen. The ability of the added proteins to compete for binding of the antisera to the immobilized protein is compared to the ability of the antigen to compete with itself. The percent crossreactivity for the above proteins is calculated, using standard calculations. Those antisera with less than 10% crossreactivity with each of the added proteins listed above are selected and pooled. The cross-reacting antibodies are optionally removed from the pooled antisera by immunoabsorption with the added considered proteins, e.g., distantly related homologs. The immunoabsorbed and pooled antisera can then be used in a competitive binding immunoassay as described above to compare a second protein, thought to be perhaps an allele or polymorphic variant of an antigen, to the immunogen protein. In order to make this comparison, the two proteins are each assayed at a wide range of concentrations and the amount of each protein required to inhibit 50% of the binding of the antisera to the immobilized protein is determined. If the amount of the second protein required to inhibit 50% of binding is less than 10 times the amount of the antigen that is required to inhibit 50% of binding, then the second protein is said to specifically bind to the polyclonal antibodies generated to antigen.
  • A signal from a direct or indirect label can be analyzed, for example, using a spectrophotometer to detect color from a chromogenic substrate; a radiation counter to detect radiation such as a gamma counter for detection of 1251; or a fluorometer to detect fluorescence in the presence of light of a certain wavelength. Where the label is a radioactive label, means for detection include a scintillation counter or photographic film as in autoradiography. Where the label is a fluorescent label, it can be detected by exciting the fluorochrome with the appropriate wavelength of light and detecting the resulting fluorescence. The fluorescence can be detected visually, by the use of electronic detectors such as charge coupled devices (CCDs) or photomultipliers and the like. Similarly, enzymatic labels can be detected by providing the appropriate substrates for the enzyme and detecting the resulting reaction product. Colorimetric or chemilluminescent labels can be detected simply by observing the color associated with the label. Thus, in various dipstick assays, conjugated gold often appears pink, while various conjugated beads appear the color of the bead. For detection of enzyme-linked antibodies, a quantitative analysis can be made using a spectrophotometer such as an EMAX Microplate Reader (Molecular Devices; Menlo Park, Calif.) in accordance with the manufacturer's instructions. If desired, the assays of the present invention can be automated or performed robotically, and the signal from multiple samples can be detected simultaneously.
  • The antibodies can be immobilized onto a variety of solid supports, such as magnetic or chromatographic matrix particles, the surface of an assay plate (e.g., microtiter wells), pieces of a solid substrate material or membrane (e.g., plastic, nylon, paper), and the like. An assay strip can be prepared by coating the antibody or a plurality of antibodies in an array on a solid support. This strip can then be dipped into the test sample and processed quickly through washes and detection steps to generate a measureable signal, such as a colored spot.
  • One of skill in the art will appreciate that it is often desirable to minimize non-specific binding in immunoassays. Particularly, where the assay involves an antigen or antibody immobilized on a solid substrate it is desirable to minimize the amount of non-specific binding to the substrate. Means of reducing such non-specific binding are well known to those of skill in the art. Typically, this technique involves coating the substrate with a proteinaceous composition. In particular, protein compositions such as bovine serum albumin (BSA), nonfat powdered milk, and gelatin are widely used with powdered milk being most preferred.
    • Saliva Collection Apparatus and Kit
  • Embodiments of the invention described herein relate to the analysis of extracellular nucleic acids and proteins derived from a cell-free fluid phase portion of saliva. Saliva Collection, Processing, Stabilization, and Storage (SCPSS) is designed as an all-in-one kit to collect, process, stabilize, and store saliva samples for research and clinical applications such as molecular diagnostics based on protein, RNA, and DNA.
  • The presence of nucleic acids and proteins in the cell-free fluid phase portion of saliva was confirmed by the procedures described in the Examples. The quality of the detected nucleic acids and proteins meet the demand for techniques such as PCR, qPCR, microarray assays, ELISA, Western blot, etc.
  • To obtain filtered samples, subjects can be given an absorbent pad to place under their tongue for a period of time long enough to absorb saliva. Any type of absorbent pad that absorbs saliva can be used, and SCPSS will work with any animal that produces saliva. Suitable absorbent materials can include, but are not limited to, nitrocellulose, cellulose acetate, polyethersulfur fabric, cellulose fiber such as paper strips or cotton, nylon, gel foam, fiber glass, polycarbonate, polyproplene, acetate, rayon, polyester absorbent pad, or other synthetic materials capable of collecting saliva. Any other method known in the art can be used to collect saliva. For example, the spitting method can also be used as a means of collecting a sample of saliva. An alternative method of obtaining saliva samples is a method whereby saliva is sucked out of the oral cavity by means of an aspirator. Saliva that has collected in the oral cavity can also be simply dripped out into a sample vessel.
  • In an embodiment, the absorbent pad can be individually placed into a syringe having a filter attached to the end of the syringe. The filter can be any type of filter described herein capable of separating saliva into a cell-free and fluid phase, for example, a 5.0 μm hydrophilic PVDF filter (Millex-SV, Millipore). The syringe plunger can then be used to push the saliva out of the pad and through the filter into a collection tube (FIG. 7). The tubes can be pre-loaded with specific stabilizer for protein, RNA, and DNA. The tubes can also be pre-loaded with an alcohol solution. The collection apparatus can be any type of commercial collection pad. For example, the SUPER●SAL or VERSI●SAL collection devices (Oasis Diagnostics, Vancouver, Wash.) can be used to collect saliva samples and further configured to be used with a sample filtration apparatus. In other embodiments, the saliva collection device can separate samples into two or more aliquots following filtration. An exemplary device for dual separation is the ULTRA●SAL-2 saliva collection device (Oasis Diagnostics, Vancouver, Wash.) (FIG. 13).
  • An embodiment describes the apparatus described herein in a method of for collecting saliva. The method can include inserting the sample collection pad into the oral cavity for sufficient time to moisten the sample collection pad, inserting the collection pad into the receiving tube, applying sufficient force to cause the materials collected in the collection pad to pass through the filter thereby forming a filtered sample, and collecting the filtered sample into one or more receiving devices.
  • It can be appreciated that classes of compounds in addition to nucleic acid and protein can be analyzed, e.g., virus, prions, bacteria (e.g., Mycobacterium tuberculosis), carbohydrates such as sugars, lipids, fatty acids, hormones, cholesterol, metabolites, and small molecule drug compounds.
  • It can further be appreciated that the apparatus can be used to diagnose a disease in a subject. The disease can include, but is not limited to, lung cancer, breast cancer stomach cancer, liver cirrhosis, a failing kidney, ulcer cancer, ovarian cancer, uterus cancer, cervical cancer, oral cancer, esophageal cancer, thyroid cancer, larynx cancer, leukemia, colon cancer, bladder cancer, prostate cancer, bronchus cancer, pancreas cancer, caries risk, periodontitis, salivary gland disease, head cancer, neck cancer, skin cancer, diabetes, smoking status, and infectious diseases such as hepatitis, HIV, and HCV. It can further be appreciated that the apparatus can be used to monitor pH levels in a subject. It can further be appreciated that the apparatus can be used to test for use of a drug including, but not limited to, prescription and controlled drugs, alcohol, methamphetamine, cocaine, caffeine, morphine, codeine, amphetamine, ephedrine, narcotine, DMT, and MDMA.
    • EXAMPLES
  • The methods system herein described are further illustrated in the following examples, which are provided by way of illustration and are not intended to be limiting.
    • Example 1: Direct Saliva Transcriptome Analysis (DSTA)
  • Standard operating procedures for salivary transcriptomic analysis require low temperatures and lengthy mRNA isolation processes. This example describes a streamlined, ambient-temperature processing, stabilization, and storage protocol for clinical analysis of salivary RNA.
    • Materials and Methods DSTA Protocol
  • Direct Saliva transcriptome analysis (DSTA) procedures, including processing, stabilization, and storage of saliva samples, were performed at ambient temperatures and used saliva supernatant (SS) instead of isolated mRNA for saliva transcriptomic detection. SS was prepared by centrifuging collected unstimulated whole saliva at 2600 g for 15 min at 4° C., followed by aspiration from the pellet. The harvested cell-free SS was then sealed and stored in a cool, dry environment at ambient temperature without stabilizing reagent until use. The salivary mRNA was directly detected by a reverse transcription quantitative real-time PCR (RT-qPCR) assay with the stored SS used as the template.
    • Saliva Sample Collection and Processing
  • Saliva samples were collected, according to protocols approved by an institutional review board, from 5 healthy individuals (mean age 34 years) who gave informed consent. None of the individuals had a history of malignancy, immunodeficiency, autoimmune disorder, hepatitis, or HIV infection (Table 1).
  • TABLE 1
    Information of samples used for evaluation of DSTA
    performance and salivary mRNA stability
    Sample ID Ethnicity Age Gender Smoking Diagnosis
    SalivaSup-1 Asian 34 M NO Normal
    SalivaSup-2 Asian 32 M NO Normal
    SalivaSup-3 Caucasian 33 M NO Normal
    SalivaSup-4 Asian 33 F NO Normal
    SalivaSup-5 Asian 38 M NO Normal
    Abbreviations:
    M: Male;
    F: Female.
  • Unstimulated whole saliva samples were collected between 9 and 10 AM as described previously (Navazesh M, Ann. NY Acad. Sci 694: 72-7 (1994)), and processed with centrifugation to obtain cell-free SS (Li et al. J. Dent. Res. 183:199-203 (2004)). The absence of cells in the harvested SS was confirmed by microscopy. The collected SS of each study participant was then split into 3 aliquots (300 μL each) as diagrammed in FIG. 1. Aliquot #1 was directly transferred into a 1.5-mL microcentrifuge tube and stored. Aliquots #2 and #3 were immediately processed by DNase treatment and salivary mRNA isolation, respectively. The DNase-treated SS (product from aliquot #2) was employed as a contrast group to reflect DNA interference in the raw SS (product from aliquot #1). Isolated mRNA (product from aliquot #3) was applied to standard procedures of saliva RNA detection, and was employed as a positive control to evaluate the DSTA method performance. All the SS samples (products from aliquots #1 and #2) were stored at room temperature (25° C.) without stabilizing reagent, and the isolated mRNAs were frozen at −80° C. until use. At day 0 (i.e., the day that all samples were collected), and after 1, 2, and 10 weeks of storage, the RT-qPCR assay was used in all samples to detect mRNA expression levels of 3 saliva internal reference genes (SIRGs): glyceraldehyde-3-phosphate dehydrogenase (GAPDH), 9 actin, beta (ACTB), and ribosomal protein S9 (RPS9). The effectiveness of the DSTA method was assessed by comparing mRNA expression levels from 3 SIRGs obtained from raw SS and isolated mRNA. The stability of salivary mRNA stored at ambient temperature without stabilizing reagent was evaluated by detecting the change of each mRNA expression level in raw SS during 10 weeks of storage.
  • A case-control salivary biomarker study was further conducted to examine the feasibility of clinical applications of the DSTA method associated with long-term ambient temperature storage. Ninety samples were collected from 3 institutions, including 27 samples from patients with oral squamous cell carcinoma (OSCC) and 63 samples from healthy controls (see Table 2).
  • TABLE 2
    Information of samples used for DSTA oral cancer mRNA biomarkers
    validation.
    Validation
    Sample ID Ethnicity Age Gender Smoking Diagnosis
    V-OralCAN-001 Caucasian 59 M NO OSCC
    V-OralCAN-002 Caucasian 76 M YES OSCC
    V-OralCAN-003 Caucasian 64 F YES OSCC
    V-OralCAN-004 Caucasian 61 M YES OSCC
    V-OralCAN-005 Caucasian 59 M YES OSCC
    V-OralCAN-006 Caucasian 60 M YES OSCC
    V-OralCAN-007 Caucasian 59 M NO OSCC
    V-OralCAN-008 Caucasian 65 M NO OSCC
    V-OralCAN-009 Hispanic 77 M YES OSCC
    V-OralCAN-010 Caucasian 68 F NO OSCC
    V-OralCAN-011 Caucasian 68 M NO OSCC
    V-OralCAN-012 Caucasian 59 M NO OSCC
    V-OralCAN-013 Caucasian 65 F NO OSCC
    V-OralCAN-014 Caucasian 74 M YES OSCC
    V-OralCAN-015 Caucasian 51 M YES OSCC
    V-OralCAN-016 Caucasian 78 M YES OSCC
    V-OralCAN-017 Caucasian 51 M NO OSCC
    V-OralCAN-018 Caucasian 70 M YES OSCC
    V-OralCAN-019 Caucasian 84 M YES OSCC
    V-OralCAN-020 Asian 54 F NO OSCC
    V-OralCAN-021 Caucasian 81 M NO OSCC
    V-OralCAN-022 Caucasian 63 M NO OSCC
    V-OralCAN-023 Caucasian 66 M NO OSCC
    V-OralCAN-024 Caucasian 52 M YES OSCC
    V-OralCAN-025 Hispanic 71 M NO OSCC
    V-OralCAN-026 Hispanic 49 M NO OSCC
    V-OralCAN-027 Caucasian 71 M NO OSCC
    V-Ctrl-001 Caucasian 65 M NO Normal
    V-Ctrl-002 Caucasian 66 M YES Normal
    V-Ctrl-003 Caucasian 65 F NO Normal
    V-Ctrl-004 Caucasian 56 F NO Normal
    V-Ctrl-005 Caucasian 62 M YES Normal
    V-Ctrl-006 Caucasian 69 M NO Normal
    V-Ctrl-007 Caucasian 74 M NO Normal
    V-Ctrl-008 Caucasian 62 M NO Normal
    V-Ctrl-009 Caucasian 80 M YES Normal
    V-Ctrl-010 Caucasian 52 M NO Normal
    V-Ctrl-011 Caucasian 69 M YES Normal
    V-Ctrl-012 Caucasian 75 M NO Normal
    V-Ctrl-013 Hispanic 54 M YES Normal
    V-Ctrl-014 Caucasian 57 F NO Normal
    V-Ctrl-015 Caucasian 72 M NO Normal
    V-Ctrl-016 Asian 37 M NO Normal
    V-Ctrl-017 Hispanic 64 M YES Normal
    V-Ctrl-018 Hispanic 45 M NO Normal
    V-Ctrl-019 Caucasian 56 F NO Normal
    V-Ctrl-020 Caucasian 59 M NO Normal
    V-Ctrl-021 Caucasian 60 M NO Normal
    V-Ctrl-022 Hispanic 63 M YES Normal
    V-Ctrl-023 Caucasian 57 M YES Normal
    V-Ctrl-024 Caucasian 72 M YES Normal
    V-Ctrl-025 Caucasian 62 M NO Normal
    V-Ctrl-026 Caucasian 66 M NO Normal
    V-Ctrl-027 Caucasian 72 M NO Normal
    V-Ctrl-028 Caucasian 56 M YES Normal
    V-Ctrl-029 Hispanic 62 F NO Normal
    V-Ctrl-030 Caucasian 57 M YES Normal
    V-Ctrl-031 Caucasian 45 M NO Normal
    V-Ctrl-032 Caucasian 54 F YES Normal
    V-Ctrl-033 Caucasian 52 M YES Normal
    V-Ctrl-034 Caucasian 62 M YES Normal
    V-Ctrl-035 Caucasian 55 M YES Normal
    V-Ctrl-036 Caucasian 70 M NO Normal
    V-Ctrl-037 Caucasian 67 F NO Normal
    V-Ctrl-038 Hispanic 35 M NO Normal
    V-Ctrl-039 Caucasian 81 M NO Normal
    V-Ctrl-040 Caucasian 59 F YES Normal
    V-Ctrl-041 Caucasian 61 M NO Normal
    V-Ctrl-042 Caucasian 63 M YES Normal
    V-Ctrl-043 Caucasian 71 M NO Normal
    V-Ctrl-044 Caucasian 62 M NO Normal
    V-Ctrl-045 Caucasian 54 M YES Normal
    V-Ctrl-046 Hispanic 64 M NO Normal
    V-Ctrl-047 Caucasian 64 M YES Normal
    V-Ctrl-048 Caucasian 59 M NO Normal
    V-Ctrl-049 Caucasian 58 M YES Normal
    V-Ctrl-050 Caucasian 66 M NO Normal
    V-Ctrl-051 Caucasian 77 M YES Normal
    V-Ctrl-052 Caucasian 70 M NO Normal
    V-Ctrl-053 Asian 44 M NO Normal
    V-Ctrl-054 Caucasian 61 M YES Normal
    V-Ctrl-055 Caucasian 51 M NO Normal
    V-Ctrl-056 Caucasian 74 M YES Normal
    V-Ctrl-057 Caucasian 61 M NO Normal
    V-Ctrl-058 Caucasian 61 M YES Normal
    V-Ctrl-059 Caucasian 82 M YES Normal
    V-Ctrl-060 Caucasian 57 M NO Normal
    V-Ctrl-061 Caucasian 47 M YES Normal
    V-Ctrl-062 Caucasian 61 M YES Normal
    V-Ctrl-063 Caucasian 47 M NO Normal
    Abbreviations:
    M: Male;
    F: Female:
    OSCC: Oral squamous cell carcinoma.
      • Ninety saliva samples were recruited from three institutions: University of California, Los Angeles (UCLA), University of Southern California (USC), and the Veterans Hospital of Greater Los Angeles (VAGLA).
  • All patients had a diagnosis of primary OSCC and had not undergone chemotherapy and/or radiotherapy. The controls were matched by sex, age, ethnicity, and smoking history to the OSCC group as described in Table 3.
  • TABLE 3
    Demongraphic information for participants in the OSCC
    mRNA biomarker validation study.
    Demographic OSCC Healthy control
    variable (n = 17) (n = 63)
    Age, mean (SD), y 65.00 (9.56)   61.29 (9.82)  
    Sex, n (%)
    Male 23 (85.2) 55 (87.3)
    Female  4 (14.8)  8 (12.7)
    Ethnicity, n (%)
    White 23 (85.2) 54 (85.7)
    Hispanic  3 (11.1)  7 (11.1)
    Asian 1 (3.7) 2 (3.2)
    Smoking, n (%)
    Yes 12 (44.4) 27 (42.9)
    No 15 (55.6) 36 (57.1)
  • The saliva collection procedures were approved by the ethics review boards and institutional review boards of all participating institutions. All participants provided written informed consent before sample collection. In this study, we used mRNAs from 7 OSCC salivary biomarker genes: human H3 histone family 3A (H3F3A), interleukin1-beta (IL1B), interleukin 8 (IL8), ornithine decarboxylase antizyme 1 (OAZ1), spermidine/spermine N1-acetyltransferase 1 (SAT1), dual specificity phosphatase1 (DUSP1), and S100 calcium binding protein P (S100P) (Li et al. Clin. Cancer Res. 10:8442-50 (2004)). These biomarker genes were used as the proof-of-concept markers and tested in all study participants. Quantification of the 7 transcripts in 90 samples was performed concurrently by standard and DSTA methods at day 0 and after 10 weeks of ambient temperature storage without a stabilizing reagent. The feasibility of the DSTA method for the clinical applications was evaluated by the numbers of markers that could be discriminated, and their diagnostic performances were compared to the results obtained by standard procedures.
    • DNase Treatment
  • Genomic DNA was eliminated in 40 μL SS (FIG. 1, aliquot #2 of each study participant) by rigorous DNase treatment using a TURBO DNA-free TM kit (Applied Biosystems) followed by DNase inactivation according to the manufacturer's instructions. The effect of DNA removal was demonstrated by applying human cell genomic DNA (300 μg/mL) to the above DNase treatment procedures. (FIG. 2).
  • Salivary mRNA Isolation
  • Salivary mRNA was isolated from 300 μL SS (FIG. 1, aliquot #3 of each study participant) using a King-Fisher® instrument (Thermo Electron Corporation) with a MagMAX Viral RNA Isolation Kit® (Applied Biosystems). The isolated mRNA was then treated with a TURBO DNA-free kit, followed by DNase inactivation to remove DNA contamination. The purity of the isolated mRNA was assessed by use of the A260/A280 ratio (accepted range: 1.8-2.0) with an ND-1000 spectrophotometer (Thermo Scientific). The complete removal of DNA in the isolated mRNA was demonstrated by qPCR without reverse transcription (see FIG. 2). Furthermore, the quality of isolated mRNAs was evaluated by detecting GAPDH, ACTB, and RPS9 mRNA expression levels using an RT-qPCR assay. Only those samples exhibiting PCR products for all 3 genes were used for subsequent analyses (Li et al. Clin. Cancer Res. 10:8442-50 (2004)).
    • RT-qPCR
  • A 2-step RT-qPCR (reverse transcription-PCR (RT-PCR) followed by qPCR operated separately) was performed for detection of salivary transcriptomes. Multiplex RT-PCR preamplification of 3 SIRG mRNAs was performed by using a SuperScript III platinum qRT-PCR System (Invitrogen) with a pool of outer primer sets (200 nmol/L for each; see Table 4), and conducted by a GeneAmp PCR-System 9700 (Applied Biosystems) with a fixed thermal cycling program (see Table 5). Each study participant provided 6 L raw SS, 7.08 μL DNase-treated SS, and 2 μL isolated mRNA as 3 different templates for RT-PCR, in which the samples were equalized by the mRNA volume. In addition to the 15 experimental RT-PCR samples (5 study participants 3 templates per study participant), a negative control with nuclease-free water as the reactive template (i.e., a blank group) was prepared. The total volume of each reaction was 30 μL adjusted by nuclease free water. The RT-PCR products were purified by ExoSAP-IT (USB) and immediately applied to qPCR or stored at −20° C. until use.
  • TABLE 4
    Primers of 3 SIRGs and 7 OSCC salivary transcripts
    Gene NCBI Amplicon
    Symbol Accession No. Primer Sequence (5' to 3') size (bp)
    GAPDH NM_002046 OF: CCTCAACGACCACTTTGTCA 59
    OR: ATGTGGGCCATGAGGTCC
    IF: ACCACTTTGTCAAGCTCATTTCCT
    IR: CACCCTGTTGCTGTAGCCAAAT
    ACTB NM_001101 OF: GATCATTGCTCCTCCTGAGC 92
    OR: CGGACTCGTCATACTCCTGC
    IF: CTCCTGAGCGCAAGTACTCC
    IR: ATACTCCTGCTTGCTGATCCAC
    RPS9 NM_001013 OF: ATCTCGTCTCGACCAAGAGC 58
    OR: TTTGACCCTCCAGACCTCAC
    IR: CGACCAAGAGCTGAAGCTGAT
    IR: CCAGACCTCACGTTTGTTCC
    H3F3A NM_002107 OF: AGCGTCTGGTGCGAGAAATT 71
    OR: GCACACAGGTTGGTGTCTTCAA
    IF: CGCTTCCAGAGCGCAGCTAT
    IR: TCTTCAAAAAGGCCAACCAGAT
    IL1B NM_000576 OF: GTACCTGTCCTGCGTGTTGAAAG 84
    OR: TTCTATCTTGTTGAAGACAAATCGCTT
    IF: TGTTGAAAGATGATAAGCCCACTCT
    IR: CAAATCGCTTTTCCATCTTCTTCT
    IL8 NM_000584 OF: TTTCTGATGGAAGAGAGCTCTGTCT 89
    OR: ATCTTCACTGATTCTTGGATACCACA
    IR: CCAAGGAAAACTGGGTGCAG
    IR: CTTGGATACCACAGAGAATGAATTTTT
    OAZ1 NM_004152 OF: TGCGAGCCGACCATGTC 73
    OR: CCCCGGTCTCACAATCTCAA
    IF: TCTTCATTTGCTTCCACAAGAACC
    IR: TCAAAGCCCAAAAAGCTGAAG
    SAT1 NM_002970 OF: CGTGATGAGTGATTATAGAGGCTTTG 85
    OR: GGTTCATTCCATTCTGCTACCAA
    IR: TTGGCATAGGATCAGAAATTCTGAA
    IR: TCTGCTACCAAGAAGTGCATGCT
    DUSP1 NM_004417 OF: CCTGTGGAGGACAACCACAAG 75
    OR: GCCTGGCAGTGGACAAACA
    IF: CAGACATCAGCTCCTGGTTCAA
    IR: CAAACACCCTTCCTCCAGCAT
    S100P NM_005980 OF: GCACGCAGACCCTGACCA 72
    OR: CGTCCAGTCCTTGAGCAATT
    IF: GCTGATGGAGAAGGAGCTACCA
    IR: TTGAGCAATTTATCCACGGCAT
    Abbreviations:
    NCBI: National Center or Biotechnology Information; O: outer, I: inner; F: forward; R: reverse
    Amplicon size: The product size yielded by IF + IR
  • TABLE 5
    Thermal cycling program for RT-PCR preamplification.
    Temperature (° C.) Time Cycle
    60  2 min 1
    50 30 min
    95  2 min
    95 15 sec 15
    50 30 sec
    60 10 sec
    72 10 sec
    72 10 min 1
    4 Forever
  • SYBR Green qPCR was performed to quantitatively detect the expression levels of salivary transcripts. The qPCR sample was prepared by combining 2×qPCR Mastermix (Applied Biological Materials), inner primers (900 nmol/L; see Table 4), and 2 μL cDNA template. The total volume of each reaction was 10 μL adjusted by nuclease-free water. The qPCR associated with melting-curve analysis was conducted by use of an AB-7500HT System (Applied Biosystems) with a fixed thermal-cycling program (Table 6). Each gene was tested in triplicate for all samples, including the negative control in which the cDNA template was the product of negative control in RT-PCR preamplification. All primers used in RT-qPCR were designed with intron spanning by use of PRIMER3 software and produced by Sigma after a BLAST search.
  • TABLE 6
    Thermal cycling program for qPCR.
    Mode Temperature (° C.) Time Cycle
    Hot Start 95 20 sec 1
    qPCR 95  3 sec 40
    (Quick AB 7500) 60 30 sec
    Disassociation Stage 95 15 sec 1
    60  1 min
    95 15 sec
    60 15 sec
    • Statistical Analysis
  • The expression levels of 3 SIRG mRNAs and 7 OSCC salivary transcripts detected by the streamlined and standard procedures were analyzed by raw quantification cycle (Cq) values. All qPCR experiments were performed in triplicate and presented as mean (SD) Cq. Statistical comparison by ANOVA was performed at a significance level of P<0.05 based on the Wilcoxon signed-rank test. In the case-control salivary biomarker study, the transcript was validated when it showed a significantly different level (P<0.05) between the OSCC patients and controls. In addition, the ROC curve was constructed and the value of the area under the curve (AUC) was calculated by numerical integration of the ROC curve using MedCalc software for each transcript detected. The P values between OSCC and controls combined with AUC values represent the diagnostic performance of the biomarker.
    • Results
  • To explore whether salivary transcriptomes can be directly detected without the need for RNA isolation, cell-free SS was used as a template to detect mRNA expression levels for 3 SIRGs and compared the results to results obtained with standard procedures. The results shown in FIG. 3 are for detection performed immediately after saliva samples were collected (day 0). The Cq value in the water group is the mean of triplicate qPCR experiments, and showed 33 for all 3 genes. In addition, the water group did not show any peak in the melting-curve analysis (data not shown), no matter which SIRG primers were used, indicating there was no reagent contamination during the RT-qPCR procedures. The Cq value of each gene in the experimental setups (SS (DSTA), SS+DNase, and isolated mRNA) was the mean of results for samples from 5 healthy study participants, each of which was assayed in triplicate (total 15 data points). The Cq values obtained from the raw SS (DSTA) were 22.84 (2.36), 21.57 (1.63), and 20.35 (1.39), whereas the Cq acquired from isolated mRNAs were 25.28 (1.44), 23.16 (2.2), and 21.42 (1.33) for GAPDH, ACTB, and RPS9, respectively. The P values obtained by comparing the Cq values from SS (DSTA) and isolated mRNA for each SIRG were 0.092, 0.233, and 0.247 for GAPDH, ACTB, and RPS9, respectively. To ensure that the obtained Cq values resulted from the specific mRNA without genomic DNA interference, melting-curve analyses were conducted along with each qPCR run. A single peak with similar melting temperature was observed for the same gene in all samples (data not shown). Furthermore, when we compared the Cq values of the SIRGs in the DNase-treated SS group to the values for the SS(DSTA) group, the P values were 0.645, 0.13, and 0.58 for GAPDH, ACTB, and RPS9, respectively (FIG. 3; P value: SS (DSTA) vs SS+DNase). These results indicated that the results in the SS (DSTA) group were exclusively from the mRNA without DNA interference, and the performance of the DSTA method was comparable to the standard procedures for salivary mRNA detection. It should be noted that both the outer and inner primers of SIRGs were designed by intron spanning, which provided additional specificity to the mRNA assays.
  • To evaluate the stability of saliva mRNA at room temperature without stabilizing reagent and/or nuclease inhibitor, saliva samples were stored at 25° C. (laboratory ambient temperature), and the 3 SIRG mRNA expression levels were assayed by using RT-qPCR at day 0 and after 1, 2, and 10 weeks of storage. As shown in FIG. 4 for the 3 SIRGs evaluated, the mean Cq values detected by SS (DSTA) increased slightly after 10 weeks of preservation and showed no significant difference throughout the time course (P>0.05; FIG. 4; P values: SS(DSTA)-Week X vs SS (DSTA)-Day 0 at X10). In addition, the Cq values obtained by using SS were all similar to those detected by isolated mRNA(P>0.05) at each time point (FIG. 4; P value: SS(DSTA) vs isolated mRNA at day 0 and weeks 1, 2, and 10). DNase-treated SS samples were used to assess DNA contamination for the duration of ambient temperature storage. As shown in FIG. 4, the mean Cq values were all similar to the results detected by raw SS(P>0.05) at each time point, indicating no DNA interference was present in the DSTA procedure (FIG. 4; P values: SS (DSTA) vs SS+DNase at day 0 and weeks 1, 2, and 10). These results demonstrated that mRNA in SS can be stable at ambient temperature in the absence of stabilizing reagent for up to 10 weeks without significant degradation, and analyzed by the DSTA method.
  • With the observed performance of the DSTA method, the feasibility of DSTA was evaluated in a clinical study. Ninety saliva samples (27 from OSCC patients and 63 from matched controls) were assayed for 7 previously identified OSCC salivary RNA markers: SAT1, OAZ1, H3F3A, IL1B, IL8, DUSP1, and S100P (Li et al. Clin. Cancer Res. 10:8442-50 (2004)). To examine the effect of long-term ambient temperature storage on marker discrimination, 7 salivary transcripts by the were assayed by the DSTA method at day 0 (i.e., immediately after sample collection) and after 10 weeks of room temperature storage without stabilizing reagent. Identification of the 7 salivary transcripts by using standard procedures was performed in parallel as the positive control. The quantitative distributions of Cq values for each transcript in healthy controls and patients with OSCC are shown in FIG. 5 and statistically described in Table 7.
  • TABLE 7
    Statistical analyses of 7 OSCC salivary mRNA biomarkers
    assayed by the streamlined and standard procedures and
    detected at day 0 and after 10 weeks of storage.
    Standard DSTA day 0 DSTA week 10 at room
    procedures (Saliva Temperature
    (Isolated mRNA) supernatant) (Saliva supernatant)
    Gene symbol P AUC ΔCqb P AUC ΔCq P AUC ΔCq
    H3F3A 0.004b 0.655 1.77 <0.001c 0.718 2.8 0.012c 0.669 2.3
    IL1B 0.002b 0.677 1.73 0.015c 0.745 2.8 0.022 0.707 3.2
    IL8 0.005b 0.655 1.78 <0.001c 0.805 3.6 0.005c 0.712 3.6
    OAZ1 0.003b 0.688 1.59 0.014c 0.684 1.7 0.345 0.560 0.8
    SAT1 0.044b 0.667 1.40 0.028c 0.728 2.0 0.085 0.650 1.7
    DUSP1 0.008b 0.644 1.56 0.214 0.585 1.7 0.048c 0.636 2.8
    S100P 0.092 0.611 0.93 0.008c 0.693 1.8 0.025c 0.662 2.0
    aRT-qPCR was performed to validate the 7 previously identified OSCC biomarkers in an independent clinical saliva sample, including 27 OSCC patients and 63 healthy controls.
    bΔCq: the mean Cq value of 63 healthy controls - the mean Cq value of 27 OSCC patients.
    cThe marker is validated if P < 0.05 based on Wilcoxon signed-rank test.
  • All 7 salivary oral cancer RNA markers exhibited upregulation in the OSCC cohort assayed by both DSTA and standard procedures. By standard procedures, 6 of the 7 gene transcripts, H3F3A, IL1B, IL8, OAZ1, SAT1, and DUSP1, showed significantly different expression levels between normal and OSCC samples (P<0.05). With the DSTA method, 6 (H3F3A, IL1B, IL8, OAZ1, SAT1, and S100P) and 5 (H3F3A, IL1B, IL8, DUSP1, and S100P) of the 7 oral cancer markers were validated (P<0.05) at day 0 and week 10, respectively. Five (H3F3A, IL1B, IL8, OAZ1, and SAT1) and 4 (H3F3A, IL1B, IL8, and DUSP1) of the salivary oral cancer markers were validated by both standard procedures and the DSTA method at day 0 and week 10, respectively. Of note, 4 markers (H3F3A, IL1B, IL8, and SAT1) at day 0 and 3 markers (H3F3A, IL1B, and IL8) at week 10 exhibited higher ROC-plot AUC values when assayed by use of the DSTA protocol (see Table 7 FIG. 6). These results indicate that the DSTA method is comparable to standard procedures in discrimination of oral cancer salivary mRNA biomarkers.
    • Discussion
  • Saliva RNA detection is an emerging field in molecular diagnostics (Martin et al. Cancer Res. 70:5203-6 (2010)). This study aimed to develop a robust, easy-to-use, ambient-temperature compatible, and cost-effective protocol to further advance the use of saliva transcriptomes for translational and clinical applications.
  • This study shows that 3 SIRG mRNA expression levels remained stable in ambient temperature-stored saliva supernatant for up to 10 weeks. This outcome is consistent with results showing that salivary RNAs are protected by specific mechanisms against nucleases in saliva. Without being bound by theory, this protective phenomenon may because salivary RNAs are associated with macromolecules such as mucines, AU (adenine and uridine)-rich element binding protein, salivary chaperone Hsp70, and apoptotic bodies. Exosomes may also play an important role in protecting salivary transcriptomes, which are vesicles for intercellular mRNA transfer that have been found in saliva. Exosomes may provide a shelter to confer salivary mRNA stability in the presence of extracellular RNases. Furthermore, analyses of the RNA profiles in exosomes showed that ribosomal RNA was absent and most of the RNA molecules were <200 nucleotides in length (Skog et al, Nat. Cell Biol. 10:1470 (2008)), which is in alignment with the mean size of salivary mRNA.
  • A clinical validation study of 7 oral cancer salivary mRNA biomarkers was performed previously (Li et al. Clin. Cancer Res. 10:8442-50 (2004)) to evaluate the clinical performance of the DSTA method. The number of validated salivary RNA markers was benchmarked (i.e., the transcript showing significant upregulation in OSCC patients; P<0.05) and their diagnostic performances, and compared these results with the results assayed by the DSTA method. The quality of the products obtained by standard and DSTA procedures was evaluated by running melting curves along with all qPCR assays. All samples exhibited a single peak with a similar melting temperature for the same gene, indicating that no DNA contamination, mispriming, and/or primer-dimer artifacts occurred in the experiments. When the saliva was assayed immediately after sample were collected, equal validation efficiencies (6 of 7 markers were validated) were obtained by both standard and DSTA procedures, in which 5 markers overlapped. After 10-week storage at ambient temperature, expressions of all 7 transcripts were still increased in the OSCC patients, and 4 markers were validated by both procedures. Most markers validated by the DSTA method showed higher ROC-plot AUC values than those assayed by standard procedures, even after 10 weeks of ambient temperature storage, indicating that the DSTA method can confer enhanced performance for detection of oral cancer salivary biomarkers.
    • Example 2: Proteome Stabilization in Saliva Materials and Methods Sample Collection and Processing
  • This examples shows that the salivary proteome is stable for approximately two weeks at room temperature (RT) without degradation by adding ethanol to the samples.
  • Saliva samples were collected from 10 healthy subjects. None of the subjects had any history of malignancy, immunodeficiencies, autoimmune disorders, hepatitis, and/or HIV infection, and had a mean age of 35 years. Subjects were asked to refrain from eating, drinking or using oral hygiene products for at least 1 h prior to collection. After rinsing their mouths with water, 5 mL saliva was collected from each subject into a 50 mL Falcon tube.
  • These saliva samples were filtered with a 0.45 μm PVDF membrane (Millipore, Billerica, Mass., USA) to remove cells and any debris. The flow through was collected. During the sample preparation, saliva samples were always kept on ice. FIG. 7 is the schematic diagram for the sample preparation.
  • Filtered saliva samples were then aliquoted into microcentrifuge tubes and stored at RT, 4° C. and −80° C., respectively, after the four different treatments described as following: (I) saliva samples with protease inhibitors were prepared, aliquoted and placed at RT and 4° C. for storage. All samples were made up with distilled water to keep the same volume. An aliquot saliva sample that had been stored at −80° C. with added protease inhibitors was used as positive control in all the experiments. Protease inhibitor stock solution was prepared by adding 1 Roche complete tablet (Roche Diagnostics GmbH, Roche Applied Science, Mannheim, Germany) into 1 mL distilled water. For every 1 mL saliva, 20 μL stock solution was added and briefly mixed by vortex. (II) Saliva amylase depletion was conducted according to a previous report (Deutsch et al. Electrophoresis 29:4150 (2008)). Briefly, saliva samples were eluted from starch column to deplete amylase specifically. (III) For protein denaturing experiments, saliva samples were either boiled at 95° C. for 10 min or by adding 20-time volumes absolute ethanol (Fisher Scientific, NJ, USA). Denatured samples were kept at RT for two weeks. The saliva proteins were then precipitated by centrifugation at 20,000 g for 20 min. (IV) For the non-denaturing method, every 20 μL absolute ethanol was added to 100 μL saliva. All the samples were made up to equal volume with distilled water. At different time points, 1 aliquot of saliva sample that has been kept at RT or 4° C. was moved into a −80° C. freezer and stored until further analysis.
    • Protein Concentration Measurement
  • The protein concentration of each saliva sample was measured by using the BCA Protein Assay Kit (Thermo Scientific Pierce, Ill., USA). Equal volume of each sample was loaded into a 96 well plate in duplicates. The experiment was performed according to the manufacturer's instruction and the plate was read at 562 nm.
    • SDS-PAGE and Western Blot
  • Equal volume of each saliva sample was used for SDS-PAGE and western blot. For SDS-PAGE, the 10% Bis-Tris gel was run at 150V in MES SDS Running Buffer for 1 h. Pre-stained protein standard (Invitrogen, CA, USA) was used to track protein migration. The gel was then stained with simple blue (Invitrogen, CA, USA). For western blot Zhang et al, PloS ONE 5:e15573), saliva proteins were run and transferred to a PVDF membrane using the iBlot (Invitrogen, CA, USA). The membrane was incubated with the primary antibody (mouse monoclonal antibody to actin, Sigma-Aldrich, St. Louis, Mich., USA) and then incubated with the secondary antibody (anti-mouse IgG, peroxidase-linked species-specific whole antibody from sheep) according to manufacturer's instructions, for 1 h at RT. Finally, the membrane was washed and visualized using ECL Plus detection kit (GE Healthcare, WI, USA).
    • In-Gel Trypsin Digestion and NanoLC-MS/MS Analysis
  • In-gel trypsin digestion and mass spectrometry protein identification were the same as previously described (Xiao and Wong, Bioinformation 5:294 (2011). Briefly, each cut gel slice was destained, and in-gel tryptic digestion was carried out overnight at 37° C. Tryptic peptides resulting from the digestion were then extracted and loaded to LC-MS/MS (Eksige NanoLC-2D with Thermo LTQXL) for protein identification. Spect was collected and processed by Xcalibur software v3.3.0 (Thermo Scientific, Waltham, Mass.). Combined MS and MS/MS spectra were converted from RAW to mzXML (ReAdW version 4.3.1) and submitted for database search again Human Swissprot by using X! Tandem (version 2010.04.21). The parameters for searching were enzyme trypsin, 1 missed cleavage, fixed modifications of carbamidomethyl (C), variable modifications of oxidation (M), parent ion tolerance 4 Da and fragment mass tolerance: ±0.4 Da. The criteria of two peptides and log (E-value)<−10 were used for protein identification.
    • ELISA
  • The ELISA tests for β-actin (Total β-actin Sandwich ELISA Kit, Cell Signaling Technology, Inc., MA, USA) and MP (Thermo Scientific Pierce, Ill., USA) were performed according to the manufacturer's instructions. All saliva samples were diluted 2 times with sample diluents for IL1β and 10 times for β-actin.
    • Data Analysis
  • The Graphpad Prism (Version 5.01) was used for all data analysis. P value was calculated based on T test and p<0.05 was used as cutoff for significance. One-way ANOVA was run to determine whether the groups are actually different in the measured characteristic. The signal intensity of the western blot bands was quantified by using the Image J software (NIH, Bethesda, Md., USA).
    • Results
  • Protease inhibitors are usually added during sample collection to prevent proteolysis. This investigation also assessed protease cocktail and different temperature conditions on proteome stabilization, because they are known to greatly affect the rate proteolysis (Chevalier et al, Clin. Proteomics 3:13 (2007)). Amylase removal may increase the stability of other salivary proteins and eases the characterization of low abundant proteins (Hu et al, Proteomics 6:6326 (2006). Ethanol has been fully evaluated for the stabilization of protein (Gekko and Timasheff, Biochemistry 20:4677 (1981). All these methods were tested and evaluated for their efficiency in proteome stabilization.
  • The protein concentrations of saliva samples stored at RT and −80° C. were measured. The average total protein concentration the positive control was 1.19±0.15 μg μL−1 after stored at −80 for 30 days. Saliva stored at RT for 30 days was found to have total protein concentration of 0.76±0.21 μg μL−1, 36% less than that of positive control (p=0.0063, n=5), which demonstrated that salivary proteome had been significantly degraded.
  • β-actin in human saliva was degraded when the samples when stored at RT. As shown in FIG. 8, the stability of β-actin was systematically compared among different treatments by ELISA. There was significant degradation if saliva samples were stored at RT without any treatment. After 3 days, there was only 71.72±18% left when compared to positive control. If the saliva samples were kept a 4° C. with protease inhibitors, more than 85±12% of this protein could be detected in saliva and there was no significant change from positive control. In the saliva samples stored at RT with protease inhibitors, β-actin was found to be stable for only 3 days. When saliva samples were stored at 4° C. with protease inhibitor β-actin was found stable for about 1 month without significant degradation.
  • Amylase is the most abundant protein in saliva and greatly affects the stability of other salivary proteins. After removing amylase from saliva, salivary proteins became more stable. The SDS-PAGE images of salivary proteins with and without amylase depletions are shown in FIGS. 9A and B. In FIG. 9A without amylase removal, the labeled bands a, b, c and d of lane RT were obviously weaker than that stored for 3 days at RT with 20% ethanol. All the 4 bands were quantified and then normalized to the corresponding positive control bands (FIG. 9C). The data demonstrated that there was significant difference between −80° C. and RT if no treatment was involved (p=0.024, n=4). When saliva samples were stored at RT with 20% ethanol, there was no significant change in comparison to the −80° C. samples (FIG. 9A) (p=0.31, n=4). In contrast, if amylase was removed from saliva, there was no significant degradation between either −80° C. and RT or RT with 20% ethanol (FIG. 9B) (p=0.17 and p=0.36, respectively, n−4). The western blot of β-actin in saliva after stored for 7 days also demonstrated that it became more stable after amylase removal (FIGS. 9D and E). If 20% ethanol was added, the stabilization efficiency for β-actin was better. In order to check what kind of proteins might have been protected by amylase removal, LC-MS/MS was run for the protein identification in the 4 bands of FIG. 9B lane RT. In the band a, three proteins were identified, including desmoplakin, deleted in malignant brain tumors 1 protein and syndecan-binding protein 2. In the band b, 7 proteins were found (mucin-7, tetra-peptide repeat homeobox protein 1, bactericidal/permeability-increasing protein-like 1, lactotransferrin, peroxisome proliferator-activated receptor gamma coactivator-related protein 1, alpha-2-macroglobulin, and polymeric immunoglobulin receptor). In the band c, several isoforms of immunoglobulin appeared, such as the heavy chain V-III, alpha-2, gamma-1, gamma-2 and gamma-4. Moreover, carbonic anhydrase 6, haptoglobin-related protein and cytoplasmic 1 actin were also identified. In the band d, 6 proteins were discovered. They were Ig lambda-1, Ig kappa, zymogen granule protein 16, short palate lung and nasal epithelium carcinoma-associated protein 2, Glyceraldehyde-3-phosphate dehydrogenase and L-lactate dehydrogenase.
  • We also explored the use of heat and ethanol denaturation to stabilize the salivary proteome. Saliva samples were treated either by boiling at 95° C. for 10 min or by precipitating with 20-time volumes ethanol. These saliva samples were then stored at RT. After two weeks, the β-actin in these samples were detected by western blot and compared with that of the positive control (FIG. 10A). There was no significant change after these denatured samples were kept at RT. Especially for ethanol precipitation, the stability of (3-actin was very consistent in these five samples (FIG. 10B, p=0.42, n=5), while there was a relative large deviation for the boiled saliva samples (p=0.071, n=5).
  • By comparison of these methods that have been used to stabilize salivary proteins, 20% ethanol was chosen as an optimized approach to stabilize salivary proteome at RT. By adding ethanol to the samples and keeping them at RT for different time intervals, two proteins were measured by immunoassay, including β-actin and IL1β.
  • The western blot of β-actin with different treatments was shown in FIG. 11A. Their corresponding quantifications were shown in FIG. 11B. The results showed that there was significant β-actin degradation at RT after day 3, 7 and 14 when compared to −80° C. By adding 20% ethanol to the saliva samples, protein degradation observed at RT were hindered with no significant difference found when compared to −80° C. (FIG. 11B) (p>0.05, n=8). However, after 30 days, significant degradation of β-actin was observed even though ethanol was added (p=0.0071, n=7).
  • IL1β has been verified as an oral cancer salivary biomarker, which was tested by ELISA in this study. Although there was degradation with the prolonged time period, the data in FIG. 12 showed that MP was stable at RT even after 30 days (p>0.05). By adding 20% ethanol, the stability of this protein was increased (p>0.05, n=10).
    • Discussion
  • Besides protein, there are other types of analytes in human saliva, such as RNA (19), microRNA (Michael et al, Oral Dis. 16:34 (2010)), DNA (Jiang et al., Clin. Cancer Res. 11:2486 (2005)), metabolites (Sugimoto et al., Metabolomics 6:78 (2010)), cells (Xie et al., Proteomics 7:486 (2008)) and microbes (Ryu et al., J. Oral Rehabil. 37:194 (2010)). All these analytes may influence the quality and composition of salivary proteome. For example, there are different kinds of proteases in the saliva, which could digest diverse proteins. The protease inhibitor cocktail tablets used in this investigation were designed to inhibit a broad spectrum of serine, cysteine and metalloproteases as well as calpains (Chevalier et al., Proteomics 3:13 (2007)). Microbes may also generate some metabolites that can change the composition of human salivary proteome. RNA may interact with proteins and become stable (Palanisamy et al., J. Dent. Res. 87:772 (2008)). The storage temperature will also change the activity of different proteases, which will alter the stability of different proteins. By considering all these factors, salivary proteome is facing a huge risk of being digested or changed under different circumstances.
  • The efficiency of different methods was evaluated by testing selected protein targets. In order to properly stabilize salivary proteins, the activity of salivary proteases should be inhibited. Otherwise, as shown in FIG. 9A, salivary proteins will degrade quickly.
  • In order to lower the metabolism of microbes, saliva sample should be kept at −80° C.
  • Protease inhibitors were added to hinder protein degradation because saliva samples without any treatment will be digested very quickly, although the salivary protein concentrations were significantly lower than the positive control after 30 days at RT. The data provided herein show that the addition of protease inhibitors and storage at 4° C. could effectively stabilize this protein for approximately two weeks. However, saliva samples could only be stabilized at RT for 3 days without significant change by adding protease inhibitors.
  • Upon amylase depletion, the salivary proteome became more stable. By removing amylase, salivary protein degradation at RT was not obvious when compared with that without amylase depletion (FIGS. 9A and B). In total, 24 proteins have been identified in the selected 4 gel bands, which might have been protected by amylase removal. Most of them have the molecular function of binding and catalytic activity. Amylase removal could greatly benefit the characterization of low abundant proteins (Hu et al., Proteomics 6:6326 (2006)). However, although this strategy is promising for saliva protein stabilization, there are several weaknesses for this method. Firstly, the saliva samples need additional treatment, which increased the complexity of sample collection. Secondly, the saliva samples are diluted 5-10 times after amylase depletion, which may affect the downstream analysis. Lastly, some saliva proteins may also be removed by using the starch column.
  • Denaturing of proteins kills microbes and alters the protein structure. Both heat and organic solvents can stabilize proteins by changing their structure (Polson et al, Anal. Technol. Biomed. Life Sci. 785:263 (2003). Data provided herein showed that the denatured saliva samples could be stored at RT for two weeks without significant change when compared to the positive control. Nevertheless, in terms of clinical usage, these proteins are unsuitable for some analysis, such as structure-related analysis and assay, as well as immunoassays, such as ELISA. By lowering the added volume of ethanol to 20%, the proteins in saliva could still be stabilized at RT without significant degradation for at least two weeks (FIGS. 11 and 12).
    • Example 3: Saliva Collection, Processing, Stabilization, and Storage (SCPSS)
  • Subjects were asked to refrain from eating, drinking, smoking, and oral hygiene activities for at least 2 hours prior to collection. Whole unstimulated saliva was then collected using the Oasis saliva collector “Super●SAL” (FIG. 13) for about 10-15 min. The collected saliva was then processed for respective molecular constituent (DNA, Protein and RNA) stabilization and storage.
  • The collection tubes were pre-loaded with specific stabilizers for protein, RNA and DNA. All samples can be transported and stored at room temperature.
    • Isolation of Mammalian and Microbial DNA
  • An aliquot of whole saliva (1-2 ml) was dispensed into a microfuge tube. An equal volume of 2× lysis and DNA Stabilization Buffer (Oasis Diagnostics) were added and maintained at room temperature.
    • Isolation of RNA
  • For salivary RNA and proteins, the collected saliva is pushed through a barrel where there is a filtration unit (Millipore MGGF filter, 5 μm hydrophilic PVDF membrane) at the sample filtration end serving to remove cells, microbes and debris.
  • Half of the volume of the saliva filtrate is stored in a microfuge tube at room temperature for downstream applications including direct saliva transcriptome analysis. This sample was maintained at room temperature.
    • Isolation of Polypeptides
  • Half of the collected saliva filtrate is placed in a microfuge tube, an equal volume of 40% ethanol is added to the sample. This sample can be maintained at room temperature.
    • Example 4: Analysis of Protein and Nucleic Acid from Collected Saliva Samples
  • Subjects will be asked to refrain from eating, drinking, smoking, and oral hygiene activities for at least 2 hours prior to collection. Whole unstimulated saliva will then be collected using an apparatus for the collection of saliva comprising a sample collection pad, a receiving device, and a filter connected to the receiving device. The filter is a 5 μm hydrophilic membrane that filters out cells and microorganisms.
  • The filtered sample (1-2 ml) that is free from cells, microbes, and debris will be aliquoted into two microfuge collection tubes. The first tube will have a 20% ethanol solution and the second tube will be free of ethanol. All collection activities will be conducted at ambient temperatures.
    • Protein Analysis
  • The filtered sample collected in the first tube having a 20% ethanol solution will be stored at room temperature for up to two weeks for downstream applications.
  • The filtered sample for protein analysis will have the protein concentration measured, and the sample will be used for SDS-PAGE and western blot analyses. The saliva proteins will be run and transferred to a protein membrane. The membrane containing the protein will be incubated with primary antibody and then secondary antibody. In-gel trypsin digestion and mass spectrometry will then be used to identify extracellular saliva proteins.
    • RNA Analysis
  • The filtered sample collected in the second tube without ethanol will be stored at room temperature for up to ten weeks for downstream applications, including direct saliva transcriptome analysis. The filtered samples will then be treated with DNase. RT-qPCR will then be used to analyze mRNA expression levels of extracellular saliva mRNAs. The expression levels of the salivary transcripts will be detected using standard procedures of raw quantification cycle (Cq) values. Statistical comparison by ANOVA will be performed at a significance level of P<0.05 based on the Wilcoxon signed-rank test.
  • This example describes dual analysis of protein and nucleic acids collected from saliva samples by any person that is not required to be a specially trained technician. The samples will be collected and aliquoted for both protein and nucleic analysis, and subsequently stored at room temperature prior to analysis.
  • The examples set forth above are provided to give those of ordinary skill in the art a complete disclosure and description of how to make and use the embodiments of the compositions, systems and methods of the disclosure, and are not intended to limit the scope of what the inventors regard as their disclosure. Modifications of the above-described modes for carrying out the disclosure that are obvious to persons of skill in the art are intended to be within the scope of the following claims. All patents and publications mentioned in the specification are indicative of the levels of skill of those skilled in the art to which the disclosure pertains. All references cited in this disclosure are incorporated by reference to the same extent as if each reference had been incorporated by reference in its entirety individually.

Claims (28)

1. A method for stabilizing nucleic acid and protein samples isolated from a saliva sample, the method comprising:
a) collecting a saliva sample from a subject;
b) filtering the saliva sample to produce a filtered sample that is free of cells;
c) collecting the filtered sample in at least a first and a second receiving device;
d) adding an alcohol solution to the first receiving device to produce an alcohol-containing filtered sample comprising a protein sample, with the proviso that alcohol is not added to the second receiving device to produce an alcohol-free filtered sample comprising a nucleic acid sample; wherein the protein sample and the nucleic acid sample are stabilized for at least 3 days when stored at 25 degrees Celsius; and
e) performing an analysis on the filtered sample collected in the first and second receiving devices comprising one or more of: a protein analysis on the alcohol-containing filtered sample or a nucleic acid analysis on the alcohol-free filtered sample.
2. The method of claim 1, wherein the nucleic acid is DNA.
3. The method of claim 1, wherein the nucleic acid analysis is polymerase chain reaction (PCR).
4. The method of claim 1, wherein the nucleic acid is RNA.
5. The method of claim 4, wherein the nucleic acid analysis is RT-PCR.
6. The method of claim 5, wherein the RT-PCR is reverse transcription quantitative real-time PCR (RT-qPCR).
7. The method of claim 1, wherein the alcohol solution comprises 20% ethanol.
8. The method of claim 1, wherein the protein analysis comprises western blot, mass spectrometry protein identification, or ELISA.
9. The method of claim 1, wherein the filtered sample is stored at ambient temperature.
10. The method of claim 1, wherein the filtered sample is stored at ambient temperature for at least two weeks without more than 50% degradation of proteins or nucleic acids present in the filtered sample.
11. The method of claim 1, wherein the filtered sample is stored at ambient temperature for at least two weeks without more than 25% degradation of proteins or nucleic acids present in the filtered sample
12. The method of claim 1, wherein the filtered sample is stored at ambient temperature for at least ten weeks without more than 50% degradation of proteins or nucleic acids present in the filtered sample.
13. The method of claim 1, wherein the filtered sample is stored at ambient temperature for at least ten weeks without more than 25% degradation of proteins or nucleic acids present in the filtered sample.
14. The method of claim 1, wherein the alcohol solution comprises 15-25% ethanol.
15. The method of claim 1, wherein the alcohol solution comprises 5-35% ethanol.
16. The method of claim 1, wherein the filter is selected from the group consisting of a 0.22 μm, 0.45 μm and 5.0 μm hydrophilic membrane.
17. The method of claim 16, wherein the filter is a 0.22 μm hydrophilic membrane.
18. An apparatus for the collection of saliva comprising a sample collection pad, a filter, two or more receiving devices, wherein the receiving devices are selected from an mRNA collection tube, a polypeptide collection tube, and a DNA collection tube, wherein the polypeptide collection tube comprises an ethanol solution, and the DNA collection tube comprises a DNA stabilizer, wherein the filter is operably connected to the receiving devices.
19. The apparatus of claim 18, wherein the filter is selected from the group consisting of a 0.22 μm, 0.45 μm and 5.0 μm hydrophilic membrane.
20. The apparatus of claim 19, wherein the filter is a 0.22 μm hydrophilic membrane.
21. A method of using the apparatus of claim 18, the method comprising inserting the sample collection pad into the oral cavity for sufficient time to moisten the sample collection pad, inserting the collection pad into the receiving tube, applying sufficient force to cause the materials collected in the collection pad to pass through the filter thereby forming a filtered sample, and collecting the filtered sample into one or more receiving devices.
22. A method for stabilizing nucleic acid and protein samples isolated from a saliva sample, the method comprising:
a) collecting a saliva sample from a human subject;
b) filtering the saliva sample using a 0.22 μm to 5.0 μm hydrophilic membrane to produce a filtered sample that is free of cells;
c) collecting the filtered sample in at first and a second receiving device;
d) adding an ethanol solution to the first receiving device to produce a 20% ethanol-containing filtered sample comprising a protein sample, with the proviso that alcohol is not added to the second receiving device to produce an alcohol-free filtered sample comprising a nucleic acid sample; wherein the protein sample and the nucleic acid sample are stabilized for at least 3 days when stored at 25 degrees Celsius.
23. The method of claim 22, wherein the protein sample is stabilized for at least 2 weeks when stored at 25 degrees Celsius.
24. The method of claim 22, wherein the nucleic acid sample is stabilized for at least 10 weeks when stored at 25 degrees Celsius.
25. The method of claim 22, further comprising the step of: (e) performing an analysis on the filtered samples collected in the first and second receiving devices comprising one or more of: a protein analysis on the ethanol-containing filtered sample or a nucleic acid analysis on the alcohol-free filtered sample.
26. The method of claim 22, wherein the ethanol solution comprises 15-25% ethanol.
27. The method of claim 22, wherein the ethanol solution comprises 5-35% ethanol.
28. The method of claim 22, wherein the hydrophilic membrane in 0.22 μm.
US16/015,407 2011-08-04 2018-06-22 Saliva collection, processing, stabilization, and storage method Abandoned US20190010538A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US16/015,407 US20190010538A1 (en) 2011-08-04 2018-06-22 Saliva collection, processing, stabilization, and storage method

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161515169P 2011-08-04 2011-08-04
PCT/US2012/049776 WO2013020137A1 (en) 2011-08-04 2012-08-06 Saliva collection, processing, stabilization, and storage method
US201414236963A 2014-06-23 2014-06-23
US16/015,407 US20190010538A1 (en) 2011-08-04 2018-06-22 Saliva collection, processing, stabilization, and storage method

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US14/236,963 Continuation US10023903B2 (en) 2011-08-04 2012-08-06 Saliva collection, processing, stabilization, and storage method
PCT/US2012/049776 Continuation WO2013020137A1 (en) 2011-08-04 2012-08-06 Saliva collection, processing, stabilization, and storage method

Publications (1)

Publication Number Publication Date
US20190010538A1 true US20190010538A1 (en) 2019-01-10

Family

ID=47629727

Family Applications (2)

Application Number Title Priority Date Filing Date
US14/236,963 Active 2034-11-05 US10023903B2 (en) 2011-08-04 2012-08-06 Saliva collection, processing, stabilization, and storage method
US16/015,407 Abandoned US20190010538A1 (en) 2011-08-04 2018-06-22 Saliva collection, processing, stabilization, and storage method

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US14/236,963 Active 2034-11-05 US10023903B2 (en) 2011-08-04 2012-08-06 Saliva collection, processing, stabilization, and storage method

Country Status (7)

Country Link
US (2) US10023903B2 (en)
EP (1) EP2739731A1 (en)
CN (1) CN103842506A (en)
AP (1) AP2014007466A0 (en)
AU (1) AU2012289854A1 (en)
CA (1) CA2845317A1 (en)
WO (1) WO2013020137A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2805486C (en) * 2010-07-20 2018-03-06 Becton, Dickinson And Company Method for linking point of care rapid diagnostic testing results to laboratory-based methods
US8956859B1 (en) 2010-08-13 2015-02-17 Aviex Technologies Llc Compositions and methods for determining successful immunization by one or more vaccines
RU2627383C2 (en) 2012-04-13 2017-08-08 Бектон, Дикинсон Энд Компани Additional research of samples with application of residual materials from previous test
US20160123856A1 (en) * 2013-06-12 2016-05-05 Oasis Diagnostics Corporation Rna/prtein/dna preferential fluid sample collection system and methods
US10849600B2 (en) * 2016-03-08 2020-12-01 Entech Instruments Inc. Breath condensate and saliva analysis using oral rinse
EP3713477B1 (en) * 2017-11-21 2022-07-06 MX3 Diagnostics, Inc. Saliva testing system and method
EP3742969B1 (en) 2018-03-06 2025-04-09 Entech Instruments Inc. Ventilator-coupled sampling device and method
JP7157869B2 (en) 2018-07-31 2022-10-20 エンテック インスツルメンツ インコーポレイテッド Hybrid capillary/filled trap and method of use
US11701036B2 (en) 2019-07-10 2023-07-18 MX3 Diagnostics, Inc. Saliva test strip and method
EP4097470A4 (en) 2020-01-30 2024-03-06 MX3 Diagnostics, Inc. BIOLOGICAL FLUID SAMPLE EVALUATION
CN111518797A (en) * 2020-04-30 2020-08-11 上海安五生物科技有限公司 Normal-temperature protection solution and preparation method and application thereof
WO2021236050A1 (en) 2020-05-18 2021-11-25 Baseline Global, Inc. Assay device, system, method, and kit
CN112640885B (en) * 2020-12-08 2022-04-12 河北工程大学 A room temperature preservation method for fatigued human saliva samples
CN114224392B (en) * 2021-11-23 2024-06-18 深圳市罗湖医院集团 Sampler and sampling equipment
CN115287283B (en) * 2022-09-16 2025-05-23 山东第一医科大学(山东省医学科学院) A method for simultaneously extracting DNA, RNA and protein from saliva stains
CN116296648A (en) * 2022-11-12 2023-06-23 北京毅新博创生物科技有限公司 Pretreatment reagent composition for mass spectrum detection of respiratory tract pathogen infection and detection kit thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040115692A1 (en) * 2000-04-03 2004-06-17 Cytyc Corporation Methods, compositions and apparatuses for detecting a target in a preservative solution
DE602005026273D1 (en) * 2004-04-09 2011-03-24 Vivebio Llc DEVICES AND METHODS FOR ACCEPTANCE, STORAGE AND TRANSPORT OF BIOLOGICAL SAMPLES
EP1965190A1 (en) * 2007-02-27 2008-09-03 Qiagen GmbH Fixation of a biological sample
CA2806734A1 (en) * 2010-07-26 2012-02-09 Biomatrica, Inc. Compositions for stabilizing dna, rna and proteins in saliva and other biological samples during shipping and storage at ambient temperatures
EP2598660B1 (en) * 2010-07-26 2017-03-15 Biomatrica, INC. Compositions for stabilizing dna, rna and proteins in blood and other biological samples during shipping and storage at ambient temperatures

Also Published As

Publication number Publication date
US10023903B2 (en) 2018-07-17
AU2012289854A1 (en) 2014-03-06
CA2845317A1 (en) 2013-02-07
US20140329705A1 (en) 2014-11-06
AP2014007466A0 (en) 2014-02-28
WO2013020137A1 (en) 2013-02-07
CN103842506A (en) 2014-06-04
EP2739731A1 (en) 2014-06-11

Similar Documents

Publication Publication Date Title
US10023903B2 (en) Saliva collection, processing, stabilization, and storage method
Dwivedi et al. Diseases and molecular diagnostics: a step closer to precision medicine
US10526665B2 (en) Exosomal biomarkers diagnostic of tuberculosis
JP2006503587A5 (en)
CN107058588B (en) Genetic deafness gene detection product
JP2011525106A (en) Markers for diffuse B large cell lymphoma and methods of use thereof
CN114292909B (en) Application of SNP rs241970 as a target in the development of a kit for screening high-altitude pulmonary edema susceptible populations
KR20180028028A (en) Composition and method for improving sensitivity and specificity on detection of nucleic acids with using dCas9 protein and gRNA for binding to target nucleic acid sequence
JP2018512868A (en) Metagenomic compositions and methods for breast cancer detection
WO2013060005A1 (en) Method for detecting specific single nucleotide polymorphism related to ankylosing spondylitis and kit therefor
CN116622840B (en) Application of SNP rs9594543 as target in developing kit for screening plateau pulmonary edema susceptible population
JP2008502330A (en) Diagnosis or prediction of progression of breast cancer
CN108841949B (en) Reagent kit and device for early detection and diagnosis of Parkinson&#39;s disease
WO2003076614A1 (en) Method of collecting data for deducing sensitivity to periodontal disease
JP2008534009A (en) Multiple SNP for diagnosing colorectal cancer, microarray and kit including the same, and method for diagnosing colorectal cancer using the same
CN114381517B (en) Application of detection of SNP rs12569857 polymorphism in preparation of screening kit for high altitude pulmonary edema susceptible population
CN104789673B (en) Applications of the rs1800818 in heating companion&#39;s thrombocytopenic syndromes that new bunyavirus causes are detected
CN104630379A (en) Non-small-cell lung cancer marker FAM107A and application thereof
CN104862379A (en) Detection kit for human leucocyte antigen genes
KR20180081445A (en) Method for rapidly detecting nucleic acid and rapid diagnosic method of disease using thereof
EP1716255B1 (en) A polynucleotide associated with a colon cancer comprising single nucleotide polymorphism, microarray and diagnostic kit comprising the same and method for diagnosing a colon cancer using the polynucleotide
ES2640524B1 (en) USE OF TCFL5 / CHA AS A NEW MARKER FOR THE PROGNOSIS AND / OR DIFFERENTIAL DIAGNOSIS OF ACUTE LYMPHOBLASTIC LEUKEMIES
KR20210024919A (en) Urinary exosome-derived miRNA gene biomarkers for diagnosis of BK virus nephropathy in kidney allografts and use thereof
CN103045745B (en) Application of CPPED1 gene
CN116536417B (en) Application of SNP rs9790196 as target in developing kit for screening plateau pulmonary edema susceptible population

Legal Events

Date Code Title Description
AS Assignment

Owner name: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, CALIF

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:WONG, DAVID T.;LIAO, WEI;SIGNING DATES FROM 20180722 TO 20180723;REEL/FRAME:046438/0151

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION